2,047 results on '"Buprenorphine administration & dosage"'
Search Results
2. Pharmacokinetics, pharmacodynamics and antinociceptive effects of buprenorphine following transdermal administration to horses.
- Author
-
Nelson GR, Mama KR, Weiner D, McKemie DS, Kass PH, Steinmetz SJ, and Knych HK
- Subjects
- Animals, Horses, Female, Male, Dose-Response Relationship, Drug, Buprenorphine pharmacokinetics, Buprenorphine administration & dosage, Buprenorphine pharmacology, Administration, Cutaneous, Analgesics, Opioid pharmacokinetics, Analgesics, Opioid administration & dosage, Analgesics, Opioid pharmacology
- Abstract
Objective: This study describes the pharmacokinetics and pharmacodynamics, including antinociceptive effects, of a transdermal buprenorphine solution in horses. It was hypothesized that transdermal application would lead to sustained blood concentrations and antinociceptive effects with fewer adverse effects compared with intravenous (IV) injection., Study Design: Prospective nonrandomized four-part parallel experimental study., Animals: A group of eight horses (three mares and five geldings) aged 6-12 years., Methods: Horses were administered incremental doses of 15, 30 and 45 μg kg
-1 of buprenorphine transdermal solution and a single IV dose of 5 μg kg-1 of buprenorphine with a 2 week washout period between treatments. Concentrations of buprenorphine were determined in plasma using liquid chromatography-tandem mass spectrometry and modeled using a nonlinear mixed effects population pharmacokinetic model to determine pharmacokinetic parameters. Pharmacodynamic effects, including changes in locomotor activity, heart rate, body temperature, gastrointestinal borborygmi, thermal and mechanical nociceptive thresholds were recorded. Mixed effects analysis of variance and post hoc comparisons were performed using a Bonferroni multiple comparison adjustment to assess differences in pharmacodynamic parameters between baseline and each time point within each dose group and between dose groups at the same time point., Results: Transdermal application of buprenorphine resulted in low systemic concentrations relative to IV injection. Bioavailability after transdermal application was 11%. Thermal nociceptive thresholds were significantly (p < 0.05) increased (4.3-10.7% relative to baseline) for up to 72 hours in the IV dose group, but only sporadically in the transdermal dose groups (2.5-9.9% relative to baseline). Changes in locomotor activity, heart rate and borborygmi varied over time and with dose., Conclusions and Clinical Relevance: Limited thermal antinociceptive effects were observed at the transdermal doses studied likely owing to limited absorption relative to IV dosing. Future studies may be directed toward investigating antinociceptive effects of higher transdermal doses and different application sites., (Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
3. Utilization of long-acting injectable monthly depot buprenorphine for opioid use disorder (OUD) in Kentucky, before and after COVID-19 related buprenorphine access policy changes.
- Author
-
Hammerslag LR, Talbert J, Slavova S, Lei F, Freeman PR, Marks KR, Fanucchi LC, Walsh SL, and Lofwall MR
- Subjects
- Humans, Kentucky epidemiology, Retrospective Studies, Female, Male, Adult, Middle Aged, Health Services Accessibility legislation & jurisprudence, United States epidemiology, Medicaid legislation & jurisprudence, Analgesics, Opioid administration & dosage, Analgesics, Opioid therapeutic use, Injections, Health Policy legislation & jurisprudence, Prior Authorization legislation & jurisprudence, Telemedicine, Opioid-Related Disorders drug therapy, Opioid-Related Disorders epidemiology, COVID-19 epidemiology, Buprenorphine administration & dosage, Buprenorphine therapeutic use, Delayed-Action Preparations therapeutic use, Opiate Substitution Treatment methods
- Abstract
Introduction: Long-acting injectable buprenorphine (LAI-bup) formulations have advantages over transmucosal buprenorphine (TM-bup), but barriers may limit their utilization. Several policies shifted during the COVID-19 pandemic to promote buprenorphine access. The federal government expanded telemedicine treatment for opioid use disorder and Kentucky (KY) Medicaid lifted prior authorization requirements (PAs) for LAI-bup (i.e., Sublocade®). This retrospective cohort study evaluated changes in LAI-bup access, utilization, and retention before and after these policy changes in KY., Methods: Individual-level TM-bup and LAI-bup dispensing record data from KY's prescription drug monitoring program examined LAI-bup utilization and retention, without a >30-day gap in coverage, for patients starting a new episode of LAI-bup treatment. Two key time periods were examined: pre-policy changes (Apr 1, 2019 - Dec 31, 2019) and post-policy changes (Apr 1, 2020 - Dec 31, 2020). Data on PA requests among Medicaid managed care organizations and availability of LAI-bup Risk Evaluation and Mitigation Strategy (REMS)-certified pharmacies were also obtained. A multivariable Cox proportional hazard regression model analysis compared pre- versus post-policy period treatment discontinuation., Results: The number of patients initiating LAI-bup increased from 211 to 481 over the two periods. By the end of the post-policy period, 24.3 % of eligible patients were retained on LAI-bup, versus 12.5 % in the pre-policy change period. The adjusted hazard ratio, comparing discontinuation during the post- versus pre-policy change periods, was 0.70 (95 % confidence interval: 0.55-0.89). There were also more REMS-certified pharmacies and providers in the post-policy change period., Conclusions: LAI-bup access, utilization, and retention increased after several policy changes., Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Sharon Walsh reports financial support was provided by National Institutes of Health and the Substance Abuse and Mental Health Services Administration. Lindsey Hammerslag reports administrative support and data access were provided by Kentucky Cabinet for Health and Family Services (KASPER Data Access). Michelle Lofwall reports a relationship with Berkshire Biomedical that includes: consulting or advisory. Michelle Lofwall reports a relationship with Braeburn Pharmaceuticals Inc. that includes: consulting or advisory. Michelle Lofwall reports a relationship with Journey Colab that includes: consulting or advisory. Sharon Walsh reports a relationship with Braeburn Pharmaceuticals Inc. that includes: consulting or advisory. Sharon Walsh reports a relationship with Astra Zeneca that includes: consulting or advisory. Sharon Walsh reports a relationship with Cerevel Therapeutics Inc. that includes:. Sharon Walsh reports a relationship with Opiant Pharmaceuticals Inc. that includes: consulting or advisory. Sharon Walsh reports a relationship with Pocket Naloxone that includes: consulting or advisory. Sharon Walsh reports a relationship with Titan Pharmaceuticals that includes: consulting or advisory. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024. Published by Elsevier Inc.)
- Published
- 2024
- Full Text
- View/download PDF
4. Ketamine-assisted buprenorphine initiation: a pilot case series.
- Author
-
Grande LA, Hutch T, Jack K, Mironov W, Iwuoha J, Muy-Rivera M, Grillo J, Martin SA, and Herring A
- Subjects
- Humans, Male, Adult, Pilot Projects, Female, Middle Aged, Fentanyl administration & dosage, Fentanyl therapeutic use, Administration, Sublingual, Methadone administration & dosage, Methadone therapeutic use, Ketamine administration & dosage, Buprenorphine administration & dosage, Buprenorphine therapeutic use, Opioid-Related Disorders drug therapy, Substance Withdrawal Syndrome drug therapy, Anesthetics, Dissociative administration & dosage, Anesthetics, Dissociative therapeutic use, Opiate Substitution Treatment methods
- Abstract
Background: Many people with opioid use disorder who stand to benefit from buprenorphine treatment are unwilling to initiate it due to experience with or fear of both spontaneous and buprenorphine-precipitated opioid withdrawal (BPOW). An effective means of minimizing withdrawal symptoms would reduce patient apprehensiveness, lowering the barrier to buprenorphine initiation. Ketamine, approved by the FDA as a dissociative anesthetic, completely resolved BPOW in case reports when infused at a sub-anesthetic dose range in which dissociative symptoms are common. However, most patients attempt buprenorphine initiation in the outpatient setting where altered mental status is undesirable. We explored the potential of short-term use of ketamine, self-administered sublingually at a lower, sub-dissociative dose to assist ambulatory patients undergoing transition to buprenorphine from fentanyl and methadone., Methods: Patients prescribed ketamine were either (1) seeking transition to buprenorphine from illicit fentanyl and highly apprehensive of BPOW or (2) undergoing transition to buprenorphine from illicit fentanyl or methadone and experiencing BPOW. We prescribed 4-8 doses of sublingual ketamine 16 mg (each dose bioequivalent to 3-6% of an anesthetic dose), monitored patients daily or near-daily, and adjusted buprenorphine and ketamine dosing based on patient response and prescriber experience., Results: Over a period of 14 months, 37 patients were prescribed ketamine. Buprenorphine initiation was completed by 16 patients, representing 43% of the 37 patients prescribed ketamine, and 67% of the 24 who reported trying it. Of the last 12 patients who completed buprenorphine initiation, 11 (92%) achieved 30-day retention in treatment. Most of the patients who tried ketamine reported reduction or elimination of spontaneous opioid withdrawal symptoms. Some patients reported avoidance of severe BPOW when used prophylactically or as treatment of established BPOW. We developed a ketamine protocol that allowed four of the last patients to complete buprenorphine initiation over four days reporting only mild withdrawal symptoms. Two patients described cognitive changes from ketamine at a dose that exceeded the effective dose range for the other patients., Conclusions: Ketamine at a sub-dissociative dose allowed completion of buprenorphine initiation in the outpatient setting in the majority of patients who reported trying it. Further research is warranted to confirm these results and develop reliable protocols for a range of treatment settings., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
5. Refining pain management in mice by comparing multimodal analgesia and NSAID monotherapy for neurosurgical procedures.
- Author
-
Munk A, Philippi V, Buchecker V, Bankstahl M, Glasenapp A, Blutke A, Michelakaki E, Talbot SR, Huwyler J, Jirkof P, Kopaczka M, Merhof D, Palme R, and Potschka H
- Subjects
- Animals, Mice, Male, Female, Carbazoles administration & dosage, Analgesia methods, Bupivacaine administration & dosage, Buprenorphine administration & dosage, Analgesics, Opioid administration & dosage, Drug Therapy, Combination, Anti-Inflammatory Agents, Non-Steroidal administration & dosage, Anti-Inflammatory Agents, Non-Steroidal therapeutic use, Pain Management methods, Mice, Inbred C57BL, Pain, Postoperative drug therapy, Neurosurgical Procedures adverse effects
- Abstract
While neurosurgical interventions are frequently used in laboratory mice, refinement efforts to optimize analgesic management based on multimodal approaches appear to be rather limited. Therefore, we compared the efficacy and tolerability of combinations of the non-steroidal anti-inflammatory drug carprofen, a sustained-release formulation of the opioid buprenorphine, and the local anesthetic bupivacaine with carprofen monotherapy. Female and male C57BL/6J mice were subjected to isoflurane anesthesia and an intracranial electrode implant procedure. Given the multidimensional nature of postsurgical pain and distress, various physiological, behavioral, and biochemical parameters were applied for their assessment. The analysis revealed alterations in Neuro scores, home cage locomotion, body weight, nest building, mouse grimace scales, and fecal corticosterone metabolites. A composite measure scheme allowed the allocation of individual mice to severity classes. The comparison between groups failed to indicate the superiority of multimodal regimens over high-dose NSAID monotherapy. In conclusion, our findings confirmed the informative value of various parameters for assessment of pain and distress following neurosurgical procedures in mice. While all drug regimens were well tolerated in control mice, our data suggest that the total drug load should be carefully considered for perioperative management. Future studies would be of interest to assess potential synergies of drug combinations with lower doses of carprofen., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
6. NIR-Remote Selectively Triggered Buprenorphine Hydrochloride Release from Microneedle Patches for the Treatment of Neuropathic Pain.
- Author
-
Han H, Li B, Yang R, Guo HL, Li Q, Wang H, Zheng B, Bai Y, and Yu Y
- Subjects
- Animals, Mice, Male, Transdermal Patch, Administration, Cutaneous, Drug Liberation, Drug Delivery Systems instrumentation, Nanoparticles chemistry, Nanoparticles therapeutic use, Neuralgia drug therapy, Needles, Infrared Rays therapeutic use, Buprenorphine administration & dosage, Buprenorphine pharmacokinetics, Buprenorphine therapeutic use
- Abstract
Neuropathic pain is a prevalent form of intermittent chronic pain, affecting approximately 7-10% of the global population. However, the current clinical administration methods, such as injection and oral administration, are mostly one-time administration, which cannot achieve accurate control of pain degree and drug dose. Herein, we developed near-infrared (NIR) light-responsive microneedle patches (MNPs) to spatiotemporally control the drug dose released to treat neuropathic pain according to the onset state. The mechanism of action utilizes upconversion nanoparticles to convert NIR light into visible and ultraviolet light. This conversion triggers the rapid rotation of the azobenzene molecular motor in the mesoporous material, enabling the on-demand controlled release of a drug dose. Additionally, MNs are used to overcome the barrier of the stratum corneum in a minimally invasive and painless manner, effectively promoting the transdermal penetration of drug molecules. The effectiveness of these patches has been demonstrated through significant results. Upon exposure to NIR light for five consecutive cycles, with each cycle lasting 30 s, the patches achieved a precise release of 318 μg of medication. In a mouse model, maximum pain relief was observed within 1 h of one cycle of NIR light exposure, with the effects lasting up to 6 h. The same level of precise treatment efficacy was maintained for subsequent pain episodes with similar light exposure. The NIR-controlled drugs precision-released MNPs provide a novel paradigm for the treatment of intermittent neuropathic pain.
- Published
- 2024
- Full Text
- View/download PDF
7. Opioid Use and the Risk of Ventricular Arrhythmias: A Systematic Review and Meta-Analysis.
- Author
-
Salmasi S, Igweokpala S, Douros A, Islam N, Andrade JG, and Filion KB
- Subjects
- Humans, Buprenorphine adverse effects, Buprenorphine administration & dosage, Methadone adverse effects, Methadone administration & dosage, Observational Studies as Topic, Randomized Controlled Trials as Topic, Risk Factors, Analgesics, Opioid adverse effects, Analgesics, Opioid administration & dosage, Arrhythmias, Cardiac chemically induced, Arrhythmias, Cardiac epidemiology, Arrhythmias, Cardiac prevention & control, Opiate Substitution Treatment adverse effects, Opiate Substitution Treatment methods, Opioid-Related Disorders drug therapy, Opioid-Related Disorders epidemiology
- Abstract
Background: The association between opioid use and the risk of ventricular arrhythmias (VA) is poorly understood., Aims: The objective of this study was to synthesize the evidence on the risk of VA associated with opioid use., Materials & Methods: We systematically searched the Cochrane Library, Embase, MEDLINE, and CINAHL databases in July 2022. Risk of bias was assessed using the Cochrane risk for bias tool for randomized controlled trials (RCTs) and ROBINS-I for observational studies. Certainty of evidence was assessed using GRADE., Results: We included 15 studies (12 observational, 2 post hoc analyses of RCTs, 1 RCT). Most studies focused on opioid use for maintenance therapy (n = 9), comparing methadone to buprenorphine (n = 13), and reported QTc prolongation (n = 13). Six observational studies had a critical risk of bias, and one RCT was at high risk of bias. Two studies could not be included in the meta-analysis as they reported a different outcome and studied an opioid antagonist. Meta-analysis of 13 studies indicated that the use of methadone was associated with an increased risk of VA compared to the use of buprenorphine, morphine, placebo, or levacetylmethadol (risk ratio [RR], 2.39; 95% CI, 1.31-4.35; I
2 = 60%). The pooled estimate varied greatly between observational studies (RR, 2.12; 95% CI, 1.15-3.91; I2 = 62%) and RCTs (RR, 14.09; 95% CI, 1.52-130.61; I2 = 0%), but both indicated an increased risk., Conclusion: In this systematic review and meta-analysis, we found that methadone use is associated with more than twice the risk of VA compared to comparators. However, our findings should be interpreted cautiously given the limited quality of the available evidence., (© 2024 The Author(s). Pharmacoepidemiology and Drug Safety published by John Wiley & Sons Ltd.)- Published
- 2024
- Full Text
- View/download PDF
8. Assessing predictors of adequate individual buprenorphine maintenance dosage for the treatment of opioid use disorder: Listening to the patient.
- Author
-
González-Saiz F, Vergara-Moragues E, Trujols J, Alcaraz S, Siñol N, and Pérez de Los Cobos J
- Subjects
- Humans, Male, Adult, Female, Cross-Sectional Studies, Middle Aged, Spain, Dose-Response Relationship, Drug, Patient Satisfaction, Analgesics, Opioid administration & dosage, Substance Withdrawal Syndrome drug therapy, Opioid-Related Disorders drug therapy, Opiate Substitution Treatment, Buprenorphine administration & dosage, Narcotic Antagonists administration & dosage, Buprenorphine, Naloxone Drug Combination administration & dosage
- Abstract
Objective: Dose optimization plays a key role in determining clinical outcomes in patients on opioid agonist treatment (OAT). The objective of this study was to identify the variables independently associated with buprenorphine/naloxone (B/N) dose adequacy in patients with opiate use disorder (OUD)., Method: Cross-sectional study of a convenience sample of patients with OUD treated with B/N (n = 315) in four regions in Spain. The Opiate Dosage Adequacy Scale (ODAS) was used to determine B/N dose adequacy. The ODAS evaluate the six components of the "dose adequacy" construct, as follows: continued use of heroin; narcotic blockade or crossed tolerance; objective opioid withdrawal symptoms (OWS); subjective OWS; craving for heroin; and overmedication. A binomial logistic regression analysis was performed to identify the variables associated with the condition "ODAS Adequate B/N dose". Participants completed a battery of instruments to assess sociodemographic, substance use, clinical, and treatment variables., Results: The B/N dose was considered adequate in 231 of the 315 participants (73.3 %). Two variables, satisfaction with B/N as a medication (OR=5.764, 95 % CI=2.211-15.030) and patient-perceived participation in B/N dose decisions (OR=1.790, 95 % CI=1221-2623), were independently, significantly, and positively associated with the "ODAS Adequate B/N dose" condition. While the severity of heroin dependence was significantly associated with buprenorphine dose adequacy in the bivariate analyses, significance was lost in the full regression model., Conclusion: Satisfaction with B/N as a medication and patient-perceived involvement in the dose decision are associated with clinician-assessed dose adequacy. In the context of good clinical practice, it is important to take into account both of these variables to individualize the prescribed dose through a shared decision-making process., Competing Interests: Declaration of competing interest Francisco Gonzalez-Saiz and José Pérez de los Cobos have received grant support for research and educational activities from Reckitt-Benckiser. All other authors declare no financial interests or potential conflicts of interest related directly or indirectly to this work., (Copyright © 2024 Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
9. Serious treatment-emergent adverse events in chronic low back pain patients treated with buprenorphine or oral opioids: a retrospective commercial claims analysis.
- Author
-
Stanicic F, Grbic D, Vukicevic D, and Zah V
- Subjects
- Humans, Retrospective Studies, Female, Male, Adult, Middle Aged, Administration, Oral, Insurance Claim Review statistics & numerical data, Transdermal Patch, Young Adult, Opioid-Related Disorders epidemiology, Opioid-Related Disorders drug therapy, Buprenorphine adverse effects, Buprenorphine administration & dosage, Buprenorphine therapeutic use, Analgesics, Opioid adverse effects, Analgesics, Opioid administration & dosage, Analgesics, Opioid therapeutic use, Low Back Pain drug therapy, Chronic Pain drug therapy
- Abstract
Aim: Explore the safety of Belbuca® (buprenorphine buccal film), buprenorphine transdermal patches and oral opioids for chronic low back pain (cLBP) treatment. Methods: The retrospective analysis of the MarketScan Commercial database (2018-2021) included treatment-naive cLBP adults. The first date of buprenorphine (Belbuca and transdermal patch) or opioid prescription was index date. Cohorts were defined based on the index medication. Observation included a 6-month pre-index period, while post-index lasted until the end of continuous insurance coverage. There were 44 relevant treatment-emergent adverse events (TEAEs) identified in the literature. Incidence rate ratio (IRR) and incidence rate difference (IRD) were used to compare serious TEAE rates (in 1000 person-years) between cohorts. Propensity-score matching minimized the selection bias. Results: Buprenorphine had lower rates of 15 serious TEAEs than oral opioids (all p ≤ 0.037), while higher rates only for serious dizziness (IRR 2.44, p = 0.011; driven by Belbuca), opioid abuse/dependence (IRR 3.13, p = 0.004; driven by patches) and cholecystitis (IRD 20.25, p = 0.044; an outlier). Additionally, a comparison between Belbuca and oral opioids showed lower rates of 13 serious TEAEs (all p ≤ 0.024) and a higher serious dizziness rate (IRR 3.17, p = 0.024). Although the rates of serious opioid abuse/dependence were similar (24.60 vs 26.93, p = 0.921), all Belbuca patients and none of the opioid patients had a positive history of these events. Belbuca also had lower rates of five serious TEAEs than transdermal patches (all p ≤ 0.018), including a serious opioid abuse/dependence (IRR 0.04, p < 0.001), but higher rates of serious cholecystitis (IRD 52.17, p = 0.035; an outlier) and suicidal ideation (IRD 156.50, p < 0.001; an outlier). Conclusion: Buprenorphine had a better safety profile than oral opioids in cLBP treatment. Belbuca showed a more favorable TEAE profile than buprenorphine transdermal patches and oral opioids.
- Published
- 2024
- Full Text
- View/download PDF
10. Women and opioid use disorder treatment: A scoping review of experiences, use of patient-reported experience measures, and integration of person-centred care principles.
- Author
-
Haynes CJ, Beck AK, Wells M, Hatton EL, Kelly PJ, Tan WJ, and Larance B
- Subjects
- Humans, Female, Patient Reported Outcome Measures, Qualitative Research, Buprenorphine therapeutic use, Buprenorphine administration & dosage, Patient-Centered Care, Opioid-Related Disorders drug therapy, Opioid-Related Disorders therapy, Opiate Substitution Treatment
- Abstract
Background: Patient-reported experience measures (PREMs) are an important aspect of assessing and improving women's experiences of person-centred care during treatment for Opioid Use Disorder (OUD). This scoping review aimed to 1) examine the extent, type, and characteristics of evidence regarding women's OUD treatment experiences, and 2) describe the extent to which PREMs and person-centred care principles are incorporated within research methods., Methods: Following Joanna Briggs Institute guidelines and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR), we conducted a scoping review to identify peer-reviewed articles on women's OUD treatment experiences. Data were extracted from 39 included studies and synthesised based on study design, method of assessment/analysis (including use of PREMs), key findings, and the integration of person-centred care principles., Results: Analysis of included studies revealed a predominance of qualitative research focused on women's experiences of pharmacological OUD treatment (methadone and/or buprenorphine) in Western countries. Women in these studies reported predominantly negative or mixed experiences of treatment. Few studies used validated PREMs and there was a lack of direct assessment or focus on recognised person-centred care principles. However, common categories of outcomes/findings identified in results across studies broadly aligned with person-centred care principles (e.g., fast access to reliable healthcare, effective treatment by trusted professionals), emphasising their applicability to women's experiences of treatment., Conclusions: Although there has been an increased focus on women's experiences of treatment for OUD in recent years, results highlighted room for improvement regarding the systematic and comprehensive assessment of women's experiences across different contexts. Given the often negative or mixed experiences reported by women, an increased focus on assessing service provision through a person-centred care lens (including utilising PREMs) may allow for service improvements or adaptations targeted towards the needs and experiences of women., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
11. Availability and Opportunities for Expansion of Buprenorphine for the Treatment of Opioid Use Disorder.
- Author
-
McKendrick G, Stull SW, Sharma A, and Dunn KE
- Subjects
- Humans, Narcotic Antagonists therapeutic use, Narcotic Antagonists administration & dosage, Analgesics, Opioid therapeutic use, United States, Buprenorphine therapeutic use, Buprenorphine administration & dosage, Opioid-Related Disorders drug therapy, Opiate Substitution Treatment methods, Health Services Accessibility
- Abstract
There is an urgent need to expand access to treatment for persons with opioid use disorder (OUD). As neurologists may frequently encounter patients with chronic pain who have developed OUD, they are in a position to serve as advocates for treatment. Buprenorphine is the most scalable medication for OUD in the United States, yet expansion has plateaued in recent years despite growing treatment needs. Reluctance of providers to establish treatment with new patients, challenges with rural expansion, stigma related to buprenorphine-based care, and pharmacy pressures that incentivize low dispensing and inventories may have stalled expansion. This review introduces these challenges before outlining actionable and evidenced-based strategies that warrant investigation, including methods to improve patient access to care (remotely delivered care, mobile delivery programs, Bridge programs) and provider retention and confidence in prescribing (expert consults, Extension for Community Healthcare Outcomes, a telementoring model, hub-and-spoke services), as well as novel innovations (virtual reality, artificial intelligence, wearable technologies). Overall, fortifying existing delivery systems while developing new transformative models may be necessary to achieve more optimal levels of buprenorphine treatment expansion., Competing Interests: In the past 3 years, KED has consulted with Mind Med, Inc., Cessation Therapeutics, and DemeRx, served on a study steering committee for Indivior, and received funding for research through her university from the National Institutes of Drug Abuse and Cure Addiction Now., (Thieme. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
12. Study protocol for the Treating Opioid Patients' Pain and Sadness (TOPPS) study - A randomized control trial to lower depression and chronic pain interference, and increase care retention among persons receiving buprenorphine.
- Author
-
Stein MD, Bendiks S, Karzhevsky S, Pierce C, Dunn A, Majeski A, Herman DS, and Weisberg RB
- Subjects
- Humans, Opiate Substitution Treatment methods, Male, Retention in Care, Behavior Therapy methods, Adult, Female, Health Education organization & administration, Health Education methods, Middle Aged, Buprenorphine therapeutic use, Buprenorphine administration & dosage, Chronic Pain drug therapy, Opioid-Related Disorders drug therapy, Opioid-Related Disorders therapy, Depression drug therapy, Depression therapy, Depression epidemiology, Analgesics, Opioid therapeutic use, Analgesics, Opioid administration & dosage
- Abstract
Background: Persons receiving prescription buprenorphine for opioid use disorder experience high rates of comorbid conditions such as chronic pain and depression, which present barriers to buprenorphine care retention. This paper describes the protocol of the TOPPS (Treating Opioid Patients' Pain and Sadness) study, which compares a values-based, behavioral activation intervention with a health education contact-control condition, with the aim of decreasing chronic pain and depression, and increasing buprenorphine care retention for persons with opioid use disorder., Methods: This randomized controlled trial (RCT) enrolls and randomizes up to 250 participants currently being treated with buprenorphine to receive three months of either TOPPS, a six-session phone-based behavioral intervention, or a health education (HE) control condition. We compare the TOPPS intervention to HE on the following outcomes: 1) pain interference and pain severity over the 3-month treatment phrase; 2) depressive symptoms over the 3-month treatment phase; and 3) sustained improvements in pain interference, depressive symptoms, and buprenorphine treatment retention over the 12-month study period. We also examine mechanisms by which the intervention may reduce pain interference., Discussion: This RCT explores a novel intervention to address chronic pain and depression for individuals receiving buprenorphine in office-based settings. TOPPS may lead to improved pain, depression, and substance use outcomes, and can utilize providers available within buprenorphine programs, broadening the disseminability of this intervention and heightening its public health impact., Clinical Trial: #NCT03698669., Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Dr. Risa Weisberg is currently the Chief Clinical Officer for RealizedCare, a digital therapeutics-based healthcare company. RealizedCare manufactures and sells behavioral health products including those for chronic pain and opioid use., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
13. Rotating Palliative Care Patients From Full Agonist Opioids to Low Dose Milligram Buprenorphine.
- Author
-
Sabharwal B, Lawal NO, and Smith MA
- Subjects
- Humans, Male, Female, Aged, Middle Aged, Analgesics, Opioid therapeutic use, Palliative Care methods, Buprenorphine therapeutic use, Buprenorphine administration & dosage
- Abstract
Competing Interests: Disclosures and Acknowledgments The authors have no conflicts of interest to disclose.
- Published
- 2024
- Full Text
- View/download PDF
14. Salivary Therapeutic Monitoring of Buprenorphine in Neonates After Maternal Sublingual Dosing Guided by Physiologically Based Pharmacokinetic Modeling.
- Author
-
Alsmadi MM
- Subjects
- Humans, Infant, Newborn, Administration, Sublingual, Female, Pregnancy, Opioid-Related Disorders drug therapy, Neonatal Abstinence Syndrome drug therapy, Adult, Buprenorphine pharmacokinetics, Buprenorphine administration & dosage, Buprenorphine analogs & derivatives, Saliva metabolism, Saliva chemistry, Drug Monitoring methods, Analgesics, Opioid pharmacokinetics, Analgesics, Opioid administration & dosage, Models, Biological
- Abstract
Background: Opioid use disorder (OUD) during pregnancy is associated with high mortality rates and neonatal opioid withdrawal syndrome (NOWS). Buprenorphine, an opioid, is used to treat OUD and NOWS. Buprenorphine active metabolite (norbuprenorphine) can cross the placenta and cause neonatal respiratory depression (EC 50 = 35 ng/mL) at high brain extracellular fluid (bECF) levels. Neonatal therapeutic drug monitoring using saliva decreases the likelihood of distress and infections associated with frequent blood sampling., Methods: An adult physiologically based pharmacokinetic model for buprenorphine and norbuprenorphine after intravenous and sublingual administration was constructed, vetted, and scaled to newborn and pregnant populations. The pregnancy model predicted that buprenorphine and norbuprenorphine doses would be transplacentally transferred to the newborns. The newborn physiologically based pharmacokinetic model was used to estimate the buprenorphine and norbuprenorphine levels in newborn plasma, bECF, and saliva after these doses., Results: After maternal sublingual administration of buprenorphine (4 mg/d), the estimated plasma concentrations of buprenorphine and norbuprenorphine in newborns exceeded the toxicity thresholds for 8 and 24 hours, respectively. However, the norbuprenorphine bECF levels were lower than the respiratory depression threshold. Furthermore, the salivary buprenorphine threshold levels in newborns for buprenorphine analgesia, norbuprenorphine analgesia, and norbuprenorphine hypoventilation were observed to be 22, 2, and 162 ng/mL., Conclusions: Using neonatal saliva for buprenorphine therapeutic drug monitoring can facilitate newborn safety during the maternal treatment of OUD using sublingual buprenorphine. Nevertheless, the suitability of using adult values of respiratory depression EC 50 for newborns must be confirmed., Competing Interests: The authors declare no conflict of interest., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
15. Comparing outcomes of extended-release naltrexone in adolescents and young adults with opioid use disorder.
- Author
-
Mitchell SG, Fletcher JB, Monico LB, Gryczynski J, Fishman MJ, O'Grady KE, and Schwartz RP
- Subjects
- Humans, Adolescent, Male, Female, Young Adult, Buprenorphine therapeutic use, Buprenorphine administration & dosage, Treatment Outcome, Opiate Substitution Treatment methods, Adult, United States epidemiology, Naltrexone therapeutic use, Naltrexone administration & dosage, Opioid-Related Disorders drug therapy, Opioid-Related Disorders epidemiology, Delayed-Action Preparations, Narcotic Antagonists therapeutic use, Narcotic Antagonists administration & dosage
- Abstract
Introduction: Opioid use among youth is a public health concern in the United States, with >3300 overdose deaths occurring nationally each year. Unfortunately, youth in the United States are still prescribed medication for opioid use disorder (OUD) at a lower rate than their adult counterparts., Methods: From 10/2013 to 01/2018, adolescents (ages 15-17; n = 25) and young adults (ages 18-21; n = 263) with moderate to severe OUD enrolled in the parent trial of extended-release naltrexone (XR-NTX; n = 82) versus treatment-as-usual (TAU; either buprenorphine maintenance [n = 94] or counseling without buprenorphine maintenance [n = 112]). The study assessed opioid use outcomes for adolescents vs. young adults using timeline follow-back self-report procedures at baseline and 3-/6-month follow-up assessments. Mixed-effects longitudinal and clustered panel regression models compared treatment effects over time of XR-NTX and TAU on opioid use outcomes in this secondary analysis., Results: Though adolescent participants reported significantly less opioid use at baseline relative to their young adult counterparts (p < 0.05), the two age groups reported similar rates of opioid use throughout the intervention period. Additionally, both adolescents and young adults receiving XR-NTX evidenced lower rates of opioid use than those receiving TAU at all time points, and adolescents on XR-NTX were the only group who reduced their opioid use at all time points. Mixed-effects models indicated adolescents receiving XR-NTX demonstrated a 48 % lower rate of opioid use days [Incidence Rate Ratio (IRR) = 0.52; p = 0.020], while young adults receiving XR-NTX reported an estimated 26 % lower rate (IRR = 0.74; p = 0.009)., Conclusions: Results indicate that adolescents respond favorably to XR-NTX relative to TAU for treatment of OUD, demonstrating similar outcomes to young adults., Competing Interests: Declaration of competing interest Dr. Schwartz has consulted for Verily Life Sciences. Dr. Monico has received research funding from Indivior. Dr. Gryczynski is part owner of COG Analytics and has received research funding (paid to his institution and including project-related salary support) from Indivior. He has received medication in kind for a NIDA-funded study from Indivior and Alkermes. Dr. Fishman has been a consultant for Alkermes, Verily Life Sciences, Drug Delivery LLC and US World Meds, and has received research funding from Alkermes and US World Meds. Drs. Mitchell, Fletcher, and O'Grady report no conflicts., (Copyright © 2023 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
16. A case of severe opioid and methamphetamine use disorder in a 14 year old.
- Author
-
Allami N, O'Connor K, and Bagley SM
- Subjects
- Humans, Adolescent, Female, Opiate Substitution Treatment methods, Narcotic Antagonists administration & dosage, Narcotic Antagonists therapeutic use, Drug Overdose, Methamphetamine, Fentanyl administration & dosage, Medication Adherence, Opiate Overdose, Opioid-Related Disorders, Buprenorphine therapeutic use, Buprenorphine administration & dosage, Amphetamine-Related Disorders
- Abstract
We present the case of a 14-year-old who established care at our primary care clinic after hospitalization for unintentional fentanyl overdose. They were diagnosed with severe opioid use disorder (OUD) and stimulant use disorder (StUD) and initiated buprenorphine while inpatient. They were then transitioned to the only known outpatient primary care clinic in her county who was actively providing medications for opioid use disorder (MOUD) in adolescents.At the first visit, they reported a history of 20 overdoses, struggling with adherence to buprenorphine and continued opioid cravings. An overdose safety plan was reviewed with them and their parent including providing them naloxone kits, fentanyl test strips, and education handout sheets. Due to their significant overdose history and adherence challenges with sublingual buprenorphine, they were started on long-acting injectable buprenorphine (LAIB) with weekly provider visits and urine toxicology screening. In collaboration with the treatment team, they initiated behavioral treatment with contingency management (CM), with incentives for appointment completion, expected urine results, and successful medication administration. Over the next 19 months, and to date, they have increasingly engaged with care and have remained abstinent. LAIB may be an appealing alternative for adolescents with OUD to improve adherence and reduce risk of recurrent use and overdose. Adjunctive treatment with CM may improve retention in MOUD and have the benefit of treating StUD. There is a need for further research to explore innovative, community-based treatment for youth with OUD., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
17. Development and Verification of a Full Physiologically Based Pharmacokinetic Model for Sublingual Buprenorphine in Healthy Adult Volunteers that Accounts for Nonlinear Bioavailability.
- Author
-
van Hoogdalem MW, Tanaka R, Johnson TN, Vinks AA, and Mizuno T
- Subjects
- Humans, Administration, Sublingual, Adult, Male, Female, Young Adult, Area Under Curve, Middle Aged, Dose-Response Relationship, Drug, Nonlinear Dynamics, Buprenorphine pharmacokinetics, Buprenorphine administration & dosage, Models, Biological, Biological Availability, Healthy Volunteers, Analgesics, Opioid pharmacokinetics, Analgesics, Opioid administration & dosage
- Abstract
Sublingual buprenorphine is used for opioid use disorder and neonatal opioid withdrawal syndrome. The study aimed to develop a full physiologically based pharmacokinetic (PBPK) model that can adequately describe dose- and formulation-dependent bioavailability of buprenorphine. Simcyp (v21.0) was used for model construction. Four linear regression models (i.e., untransformed or log transformed for dose or proportion sublingually absorbed) were explored to describe sublingual absorption of buprenorphine across dose. Published clinical trial data not used in model development were used for verification. The PBPK model's predictive performance was deemed adequate if the geometric means of ratios between predicted and observed (P/O) area under the curve (AUC), peak concentration (C
max ), and time to reach Cmax (Tmax ) fell within the 1.25-fold prediction error range. Sublingual buprenorphine absorption was best described by a regression model with logarithmically transformed dose. By integrating this nonlinear absorption profile, the PBPK model adequately predicted buprenorphine pharmacokinetics (PK) following administration of sublingual tablets and solution across a dose range of 2-32 mg, with geometric mean (95% confidence interval) P/O ratios for AUC and Cmax equaling 0.99 (0.86-1.12) and 1.24 (1.09-1.40), respectively, and median (5th to 95th percentile) for Tmax equaling 1.11 (0.69-1.57). A verified PBPK model was developed that adequately predicts dose- and formulation-dependent buprenorphine PK following sublingual administration. SIGNIFICANCE STATEMENT: The physiologically based pharmacokinetic (PBPK) model developed in this study is the first to adequately predict dose- and formulation-dependent sublingual buprenorphine pharmacokinetics. Accurate prediction was facilitated by the incorporation of a novel nonlinear absorption model. The developed model will serve as the foundation for maternal-fetal PBPK modeling to predict maternal and fetal buprenorphine exposures to optimize buprenorphine treatment for neonatal opioid withdrawal syndrome., (Copyright © 2024 by The American Society for Pharmacology and Experimental Therapeutics.)- Published
- 2024
- Full Text
- View/download PDF
18. Extended-Release 7-Day Injectable Buprenorphine for Patients With Minimal to Mild Opioid Withdrawal.
- Author
-
D'Onofrio G, Herring AA, Perrone J, Hawk K, Samuels EA, Cowan E, Anderson E, McCormack R, Huntley K, Owens P, Martel S, Schactman M, Lofwall MR, Walsh SL, Dziura J, and Fiellin DA
- Subjects
- Adult, Female, Humans, Male, Middle Aged, Analgesics, Opioid administration & dosage, Analgesics, Opioid therapeutic use, Feasibility Studies, Narcotic Antagonists administration & dosage, Narcotic Antagonists therapeutic use, Opiate Substitution Treatment methods, Buprenorphine administration & dosage, Buprenorphine therapeutic use, Delayed-Action Preparations, Opioid-Related Disorders drug therapy, Substance Withdrawal Syndrome drug therapy
- Abstract
Importance: Buprenorphine is an effective yet underused treatment for opioid use disorder (OUD)., Objective: To evaluate the feasibility (acceptability, tolerability, and safety) of 7-day injectable extended-release buprenorphine in patients with minimal to mild opioid withdrawal., Design, Setting, and Participants: This nonrandomized trial comprising 4 emergency departments in the Northeast, mid-Atlantic, and Pacific geographic areas of the US included adults aged 18 years or older with moderate to severe OUD and Clinical Opiate Withdrawal Scale (COWS) scores less than 8 (minimal to mild), in which scores range from 0 to 7, with higher scores indicating increasing withdrawal. Exclusion criteria included methadone-positive urine, pregnancy, overdose, or required admission. Outcomes were assessed at baseline, daily for 7 days by telephone surveys, and in person at 7 days. Patient recruitment occurred between July 13, 2020, and May 25, 2023., Intervention: Injection of a 24-mg dose of a weekly extended-release formulation of buprenorphine (CAM2038) and referral for ongoing OUD care., Main Outcomes and Measures: Primary feasibility outcomes included the number of patients who (1) experienced a 5-point or greater increase in the COWS score or (2) transitioned to moderate or greater withdrawal (COWS score ≥13) within 4 hours of extended-release buprenorphine or (3) experienced precipitated withdrawal within 1 hour of extended-release buprenorphine. Secondary outcomes included injection pain, satisfaction, craving, use of nonprescribed opioids, adverse events, and engagement in OUD treatment., Results: A total of 100 adult patients were enrolled (mean [SD] age, 36.5 [8.7] years; 72% male). Among the patients, 10 (10.0% [95% CI, 4.9%-17.6%]) experienced a 5-point or greater increase in COWS and 7 (7.0% [95% CI, 2.9%-13.9%]) transitioned to moderate or greater withdrawal within 4 hours, and 2 (2.0% [95% CI, 0.2%-7.0%]) experienced precipitated withdrawal within 1 hour of extended-release buprenorphine. A total of 7 patients (7.0% [95% CI, 2.9%-13.9%]) experienced precipitated withdrawal within 4 hours of extended-release buprenorphine, which included 2 of 63 (3.2%) with a COWS score of 4 to 7 and 5 of 37 (13.5%) with a COWS score of 0 to 3. Site pain scores (based on a total pain score of 10, in which 0 indicated no pain and 10 was the worst possible pain) after injection were low immediately (median, 2.0; range, 0-10.0) and after 4 hours (median, 0; range, 0-10.0). On any given day among those who responded, between 29 (33%) and 31 (43%) patients reported no cravings and between 59 (78%) and 75 (85%) reported no use of opioids; 57 patients (60%) reported no days of opioid use. Improving privacy (62%) and not requiring daily medication (67%) were deemed extremely important. Seventy-three patients (73%) were engaged in OUD treatment on day 7. Five serious adverse events occurred that required hospitalization, of which 2 were associated with medication., Conclusions and Relevance: This nonrandomized trial of the feasibility of a 7-day buprenorphine injectable in patients with minimal to mild opioid withdrawal (COWS scores, 0-7) found the formulation to be acceptable, well tolerated, and safe in those with COWS scores of 4 to 7. This new medication formulation could substantially increase the number of patients with OUD receiving buprenorphine., Trial Registration: ClinicalTrials.gov Identifier: NCT04225598.
- Published
- 2024
- Full Text
- View/download PDF
19. Considerations when prescribing opioid agonist therapies for people living with HIV.
- Author
-
Tarfa A, Lier AJ, Shenoi SV, and Springer SA
- Subjects
- Humans, Delayed-Action Preparations, Health Services Accessibility, United States, Delivery of Health Care organization & administration, Pre-Exposure Prophylaxis methods, Anti-HIV Agents administration & dosage, Anti-HIV Agents pharmacology, Opioid-Related Disorders drug therapy, HIV Infections drug therapy, Buprenorphine administration & dosage, Opiate Substitution Treatment methods, Narcotic Antagonists administration & dosage, Methadone administration & dosage, Naltrexone administration & dosage, Drug Interactions, Analgesics, Opioid administration & dosage
- Abstract
Introduction: Medications for opioid use disorder (MOUD) include opioid agonist therapies (OAT) (buprenorphine and methadone), and opioid antagonists (extended-release naltrexone). All forms of MOUD improve opioid use disorder (OUD) and HIV outcomes. However, the integration of services for HIV and OUD remains inadequate. Persistent barriers to accessing MOUD underscore the immediate necessity of addressing pharmacoequity in the treatment of OUD in persons with HIV (PWH)., Areas Covered: In this review article, we specifically focus on OAT among PWH, as it is the most commonly utilized form of MOUD. Specifically, we delineate the intersection of HIV and OUD services, emphasizing their integration into the United States Ending the HIV Epidemic (EHE) plan by offering comprehensive screening, testing, and treatment for both HIV and OUD. We identify potential drug interactions of OAT with antiretroviral therapy (ART), address disparities in OAT access, and present the practical benefits of long-acting formulations of buprenorphine, ART, and pre-exposure prophylaxis for improving HIV prevention and treatment and OUD management., Expert Opinion: Optimizing OUD outcomes in PWH necessitates careful attention to diagnosing OUD, initiating OUD treatment, and ensuring medication retention. Innovative approaches to healthcare delivery, such as mobile pharmacies, can integrate both OUD and HIV and reach underserved populations.
- Published
- 2024
- Full Text
- View/download PDF
20. Orally dissolving buprenorphine for opioid use disorder linked to caries.
- Author
-
Segelnick SL and Weinberg MA
- Subjects
- Humans, Male, Administration, Oral, United States, Analgesics, Opioid therapeutic use, Analgesics, Opioid administration & dosage, Analgesics, Opioid adverse effects, Dental Caries prevention & control, Buprenorphine therapeutic use, Buprenorphine administration & dosage, Opioid-Related Disorders drug therapy, Xerostomia chemically induced, Xerostomia drug therapy
- Abstract
Background: Buprenorphine is under scrutiny because of the development of xerostomia and caries. The purpose of this article was to inform dental care professionals about the oral effects of buprenorphine and to increase knowledge and awareness of medication-assisted treatment in the management of opioid use disorder (OUD)., Case Description: In 2022, the US Food and Drug Administration issued a warning about xerostomia and caries associated with the use of transmucosal (sublingual and buccal formulations) buprenorphine. Dental health care professionals should instruct patients taking buprenorphine on how to prevent these dental issues by means of rinsing with water and swallowing once the drug has been completely dissolved, followed by toothbrushing at least 1 hour after taking the drug. In addition, a fluoride supplement should be prescribed., Practical Implications: It is imperative for dentists to recognize buprenorphine as medication-assisted treatment and to recognize a patient as having an OUD. While taking buprenorphine, the patient should have more frequent oral health care appointments, including home care instructions and caries risk assessment to monitor for caries and xerostomia so that treatment, if indicated, could be initiated as soon as possible. In addition, the dentist's role in OUD is to make sure patients follow the treatment recommendations and use the buprenorphine and to not have them discontinue because of potential caries risk., Competing Interests: Disclosures Drs. Segelnick and Weinberg did not report any disclosures., (Copyright © 2024 American Dental Association. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
21. High-Dose Buprenorphine Initiation: A Scoping Review.
- Author
-
Wong S, Fabiano N, Webber D, and Kleinman RA
- Subjects
- Humans, Opioid-Related Disorders drug therapy, Narcotic Antagonists administration & dosage, Substance Withdrawal Syndrome, Opiate Substitution Treatment methods, Analgesics, Opioid administration & dosage, Analgesics, Opioid adverse effects, Buprenorphine administration & dosage, Buprenorphine adverse effects
- Abstract
Objective: The aim of the study is to review and synthesize the literature on high-dose buprenorphine initiation (>12-mg total dose on day of initiation)., Methods: A scoping review of literature about high-dose buprenorphine initiation was conducted. MEDLINE, Embase, PsycINFO, and Cochrane Central were searched. Randomized controlled trials, prospective and retrospective cohort studies, and case studies/reports published in English before February 13, 2023, were included., Results: Fifteen studies reporting outcomes from 580 high-dose buprenorphine initiations were included. Eight studies were in inpatient settings, 3 in emergency departments, 3 in outpatient settings, and 1 in a first-responder setting. Four studies reported high-dose initiations among individuals exposed to fentanyl. There were no reported events of fatal or nonfatal overdose or respiratory depression, although adverse event reporting was inconsistent in published reports. The most reported side effects with high-dose buprenorphine initiation were nausea or vomiting (n = 17) and precipitated withdrawal (n = 7). The most serious reported adverse event was hypotension requiring oral hydration (n = 2). Most studies reported improvements in subjective or objective withdrawal symptoms. The duration of follow-up ranged from none to 8 months., Conclusions: High-dose buprenorphine initiation has not been associated with reported cases of overdose or respiratory depression. However, the current literature about high-dose buprenorphine is limited by inconsistent side effect reporting, limited power to detect rare safety events such as respiratory depression, limited follow-up data, and few comparison studies between high-dose and regular initiation protocols. Further prospective data are needed to evaluate the safety and effectiveness of this initiation strategy., Competing Interests: The authors report no conflicts of interest., (Copyright © 2024 American Society of Addiction Medicine.)
- Published
- 2024
- Full Text
- View/download PDF
22. Injectable Buprenorphine: An Opportunity to Improve Treatment Access for Youth With Opioid Use Disorder.
- Author
-
Calihan JB and Bagley SM
- Subjects
- Humans, Adolescent, Narcotic Antagonists administration & dosage, Narcotic Antagonists therapeutic use, Injections, Buprenorphine administration & dosage, Buprenorphine therapeutic use, Opioid-Related Disorders drug therapy, Opiate Substitution Treatment methods, Health Services Accessibility
- Published
- 2024
- Full Text
- View/download PDF
23. Surgical removal of extended-release buprenorphine depot due to adverse reactions.
- Author
-
Burton A, DeBona DJ, Handzel M, Kelly-Pisciotti S, Qiao M, Rojek D, and Acquisto NM
- Subjects
- Humans, Male, Analgesics, Opioid adverse effects, Analgesics, Opioid administration & dosage, Narcotic Antagonists administration & dosage, Narcotic Antagonists therapeutic use, Narcotic Antagonists adverse effects, Adult, Female, Vomiting chemically induced, Vomiting drug therapy, Nausea chemically induced, Nausea drug therapy, Buprenorphine administration & dosage, Buprenorphine adverse effects, Delayed-Action Preparations, Opioid-Related Disorders drug therapy
- Abstract
Extended-release formulations of buprenorphine offer less frequent dosing, provide consistent medication delivery, and improve adherence for treatment of opioid use disorder (OUD). Although buprenorphine is a partial agonist with seemingly less precipitated withdrawal and easier initiation than full opioid agonists used for OUD, its use is not benign and understanding of the different extended-release formulations is necessary. We report a case of a patient that received a long-acting buprenorphine formulation (Sublocade®) administered subcutaneously that presented to the emergency department with tachycardia, hyperglycemia, elevated anion gap, and sustained nausea and vomiting refractory to pharmacotherapy requiring surgical removal of the buprenorphine depot for resolution of nausea and vomiting symptoms., Competing Interests: Declaration of competing interest None., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
24. Early Remission of Opioid Use Disorder in an Adolescent Using Buprenorphine Extended - Release Subcutaneous Injection: A Case Report.
- Author
-
Schmuhl KK, Golec A, and Ebersole AM
- Subjects
- Humans, Adolescent, Injections, Subcutaneous, Male, Opiate Substitution Treatment methods, Narcotic Antagonists administration & dosage, Narcotic Antagonists therapeutic use, Female, Buprenorphine administration & dosage, Buprenorphine therapeutic use, Opioid-Related Disorders drug therapy, Delayed-Action Preparations
- Abstract
Opioid use disorder (OUD) continues to be a major public health crisis, with the current epidemic being driven by synthetic opioids such as illicitly manufactured fentanyl. While medications exist to treat OUD, only sublingual and subdermal buprenorphine formulations are approved for patients aged 16-17 years. Furthermore, almost all pediatric patients who are diagnosed with OUD do not receive medication as treatment. This case describes the innovative use of buprenorphine extended-release subcutaneous injection in a 17-year-old with OUD who has achieved early remission after four months of treatment. This case supports the use of buprenorphine extended-release in pediatric patients who are at high risk. While buprenorphine extended-release injections are not Food and Drug Administration-approved for pediatric patients, the increase in adolescent overdose deaths and lack of access to treatment in this age group support the need for increased research and treatment options for youth with OUD., (Copyright © 2024 Society for Adolescent Health and Medicine. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
25. 'Matters-of-concern' associated with discontinuation of long-acting injectable buprenorphine: Findings from a longitudinal qualitative study.
- Author
-
Parkin S, Neale J, and Strang J
- Subjects
- Humans, Longitudinal Studies, Male, Female, Adult, Middle Aged, Interviews as Topic, Analgesics, Opioid administration & dosage, Injections, Buprenorphine administration & dosage, Opiate Substitution Treatment, Opioid-Related Disorders drug therapy, Delayed-Action Preparations, Qualitative Research
- Abstract
Background: Discontinuation of medications such as methadone and buprenorphine amongst patients receiving opioid agonist treatment (OAT) is an international phenomenon. Recent developments in OAT medication include depot-injections of buprenorphine. Circumstances underlying discontinuation of these new formulations of medication are not fully understood from a qualitative perspective., Methods: Data derive from a longitudinal qualitative study of patients' experience of long-acting injectable buprenorphine (LAIB), involving semi-structured telephone-interviews held at six-points in time. The relevant dataset for this article consists of 44 interview transcripts, generated from 8 participants who were each affected by discontinuation of LAIB prescriptions (during the first 12-months of treatment). Analyses sought to identify circumstances associated with LAIB discontinuation and data were further situated within a framework of 'evidence making intervention' and associated 'matters-of-concern'. Matters-of-concern relate to the ways in which an intervention is 'made' and constructed through engagement and practice, from the perspective of the recipient., Findings: In this study, participants experienced either 'discontinuation of LAIB prescriptions by treatment services' or patient-led 'opt-out' from treatment. Matters-of-concern underlying the former were associated with late attendance for scheduled appointments, non-prescribed substance use or receiving a custodial sentence. Matters-of-concern relating to patient-initiated discontinuation were associated with personal circumstances that affected treatment motivation, side-effects (of buprenorphine), a preference to resume heroin use, or because individual treatment goals had been achieved., Conclusion: The assorted matters-of-concern that influence discontinuation of LAIB demonstrate that such OAT is complex and multi-faceted, is neither fixed nor stable, and does not generate universally shared outcome. Experiences of LAIB discontinuation are shaped by a wide range of social, temporal and treatment-related effects that include disconnected therapeutic alliance between patient and treatment providers. In order to maximise the benefits of LAIB it is necessary to develop meaningful therapeutic alliances (notwithstanding policy boundaries) to enable exploration of matters-of-concern during treatment., Competing Interests: Declaration of competing interest During 2019–2023 (whilst employed at King's College London), S.P. was part-funded by income from research grants obtained from MundiPharma Research Ltd and Camurus AB. J.N. has received, through her university, research funding from Mundipharma Research Ltd and Camurus AB and honoraria from Indivior and Camurus AB for presentations. In the last three years, J.S. has secured, through his university, research funding from Mundipharma Research Ltd, Camurus AB, and Pneumowave (for further details, see www.kcl.ac.uk/people/john-strang)., (Copyright © 2024. Published by Elsevier B.V.)
- Published
- 2024
- Full Text
- View/download PDF
26. Neurobehavioral outcomes of infants exposed to buprenorphine-naloxone compared with naltrexone during pregnancy.
- Author
-
Mantri S, Cheng AC, Saia K, Shrestha H, Amgott R, Bressler J, Werler MM, Carter G, Jones HE, and Wachman EM
- Subjects
- Humans, Female, Pregnancy, Infant, Newborn, Adult, Buprenorphine adverse effects, Buprenorphine administration & dosage, Prenatal Exposure Delayed Effects chemically induced, Male, Buprenorphine, Naloxone Drug Combination adverse effects, Buprenorphine, Naloxone Drug Combination therapeutic use, Buprenorphine, Naloxone Drug Combination administration & dosage, Child Development drug effects, Infant, Infant Behavior drug effects, Prospective Studies, Opioid-Related Disorders drug therapy, Naloxone administration & dosage, Naloxone adverse effects, Naloxone therapeutic use, Pregnancy Complications drug therapy, Naltrexone adverse effects, Naltrexone administration & dosage, Naltrexone therapeutic use, Narcotic Antagonists adverse effects, Narcotic Antagonists administration & dosage, Narcotic Antagonists therapeutic use
- Abstract
Background: Naltrexone is a medication used to treat both opioid and alcohol use disorder with limited experience in pregnant individuals, particularly in comparison to more commonly utilized treatments such as buprenorphine-naloxone. The long-term outcomes of infants exposed to naltrexone has not been previously examined., Aims: To compare the neurobehavioral outcomes of naltrexone versus buprenorphine-naloxone exposed infants., Study Design: Multi-centered prospective cohort study., Subjects: Pregnant people on prescribed buprenorphine-naloxone or naltrexone were enrolled during pregnancy and the dyad followed until 12 months after delivery., Outcome Measures: Infants were evaluated at 4-6 weeks corrected gestational age (CGA) using the NICU Neonatal Neurobehavioral Scale (NNNS) and at the 12-month CGA visit using the Ages and Stages Questionnaire, Third Edition (ASQ-3)., Results: There were 7 dyads in the naltrexone group and 34 in the buprenorphine-naloxone group. On the NNNS, infants exposed to naltrexone had higher median scores for arousal and excitability, and lower median scores for attention and regulation at 4-6 weeks CGA compared to the buprenorphine-naloxone group. None of the infants in the naltrexone group were monitored for NOWS and had shorter length of hospital stay compared with the buprenorphine-naloxone group. Although no statistically significant differences were observed, more infants in the buprenorphine-naloxone group were identified as at risk for development delays in the communication, problem solving, and personal social domains of the ASQ-3 at 12 months CGA. Results should be interpreted with caution given this study's small sample size and lack of a prospective comparison cohort., Conclusions: In this small cohort, there are differences noted in infant neurobehavior by NNNS at 4-6 weeks of age when comparing the buprenorphine-naloxone and naltrexone groups. At 12 months, ASQ-3 scores were similar but with percentage differences in potential development delay risk observed between the two groups. Larger cohort studies are needed to determine the long-term child outcomes after naltrexone exposure in pregnancy., Competing Interests: Declaration of competing interest The authors have no conflicts of interest to disclose., (Copyright © 2024. Published by Elsevier B.V.)
- Published
- 2024
- Full Text
- View/download PDF
27. Effectiveness of buprenorphine (naloxone) for opioid dependence does not differ across opioid categories: a retrospective cohort study from India.
- Author
-
Ghosh A, Shaktan A, Basu D, Bn S, Naik SS, and Mattoo SK
- Subjects
- Humans, Retrospective Studies, Male, India, Female, Adult, Narcotic Antagonists therapeutic use, Narcotic Antagonists administration & dosage, Middle Aged, Analgesics, Opioid therapeutic use, Analgesics, Opioid administration & dosage, Treatment Outcome, Buprenorphine therapeutic use, Buprenorphine administration & dosage, Opioid-Related Disorders drug therapy, Opiate Substitution Treatment methods, Buprenorphine, Naloxone Drug Combination therapeutic use, Medication Adherence statistics & numerical data
- Abstract
We aimed to examine whether treatment retention, abstinence, and adherence to buprenorphine-naloxone (BNX) differ among individuals with opioid dependence (OD) across three common categories of opioids- heroin, opium, and low-potency pharmaceutical. In a retrospective cohort study, we analyzed outpatient treatment records from March 2020 through February 2022. Opioid category was determined by lifetime and current opioid use. We defined treatment retention as weeks of uninterrupted clinic attendance. Abstinence and BNX adherence were calculated by weeks of extra-medical opioid-negative and buprenorphine-positive urine screening from treatment initiation. Four-hundred-thirteen patients were eligible; 406 (98.3%) were included in the final analysis. Two-hundred-ninety (71.4%) patients were dependent on heroin; 66 (16.3%) were natural opioid dependent, and 50 (12.3%) were dependent on low-potency pharmaceutical opioids. BNX effectiveness in treatment retention, abstinence, and adherence did not differ in patients dependent on heroin, natural, and low-potency pharmaceutical opioids. Patients on ≥8 mg daily BNX had better retention and adherence than those on <8 mg daily. Patients from lower socioeconomic status (SES) had higher odds of retention, abstinence, and adherence than those from upper/middle SES. Treatment outcomes on BNX did not differ across opioid categories. However, BNX should be dosed adequately.
- Published
- 2024
- Full Text
- View/download PDF
28. Barriers and facilitators to use of buprenorphine in state-licensed specialty substance use treatment programs: A survey of program leadership.
- Author
-
Burke KN, Krawczyk N, Li Y, Byrne L, Desai IK, Bandara S, and Feder KA
- Subjects
- Female, Humans, Male, Attitude of Health Personnel, Cross-Sectional Studies, Drug Prescriptions statistics & numerical data, Health Personnel education, Internet, Mental Health Services, New Jersey, Program Evaluation, Self Report, Social Status, Substance Withdrawal Syndrome drug therapy, Substance Withdrawal Syndrome etiology, Substance Withdrawal Syndrome prevention & control, Surveys and Questionnaires, Buprenorphine administration & dosage, Buprenorphine economics, Buprenorphine supply & distribution, Buprenorphine therapeutic use, Leadership, Licensure, Opiate Substitution Treatment economics, Opiate Substitution Treatment statistics & numerical data, Opioid-Related Disorders complications, Opioid-Related Disorders drug therapy, Practice Patterns, Physicians' statistics & numerical data, Substance Abuse Treatment Centers economics, Substance Abuse Treatment Centers legislation & jurisprudence, Substance Abuse Treatment Centers organization & administration, Substance Abuse Treatment Centers statistics & numerical data
- Abstract
Introduction: Medications for opioid use disorder (MOUD), including buprenorphine, reduce overdose risk and improve outcomes for individuals with opioid use disorder (OUD). However, historically, most non-opioid treatment program (non-OTP) specialty substance use treatment programs have not offered buprenorphine. Understanding barriers to offering buprenorphine in specialty substance use treatment settings is critical for expanding access to buprenorphine. This study aims to examine program-level attitudinal, financial, and regulatory factors that influence clients' access to buprenorphine in state-licensed non-OTP specialty substance use treatment programs., Methods: We surveyed leadership from state-licensed non-OTP specialty substance use treatment programs in New Jersey about organizational characteristics, including medications provided on- and off-site and percentage of OUD clients receiving any type of MOUD, and perceived attitudinal, financial, and regulatory barriers and facilitators to buprenorphine. The study estimated prevalence of barriers and compared high MOUD reach (n = 36, 35 %) and low MOUD reach (n = 66, 65 %) programs., Results: Most responding organizations offered at least one type of MOUD either on- or off-site (n = 80, 78 %). However, 71 % of organizations stated that fewer than a quarter of their clients with OUD use any type of MOUD. Endorsement of attitudinal, financial, and institutional barriers to buprenorphine were similar among high and low MOUD reach programs. The most frequently endorsed government actions suggested to increase use of buprenorphine were facilitating access to long-acting buprenorphine (n = 95, 96 %), education and stigma reduction for clients and families (n = 95, 95 %), and financial assistance to clients to pay for medications (n = 90, 90 %)., Conclusions: Although non-OTP specialty substance use programs often offer clients access to MOUD, including buprenorphine, most OUD clients do not actually receive MOUD. Buprenorphine uptake in these settings may require increased financial support for programs and clients, more robust education and training for providers, and efforts to reduce the stigma associated with medication among clients and their families., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
29. An Australian retrospective observational cohort comparison of the use of long-acting injectable buprenorphine products.
- Author
-
Daglish MRC, Hayllar JS, and McDonough M
- Subjects
- Humans, Male, Retrospective Studies, Female, Adult, Australia, Middle Aged, Opioid-Related Disorders drug therapy, Opiate Substitution Treatment methods, Analgesics, Opioid administration & dosage, Injections, Young Adult, Adolescent, Buprenorphine administration & dosage, Delayed-Action Preparations
- Abstract
Introduction: In early 2019, Australia became the first jurisdiction to have two brands of long-acting injectable buprenorphine (LAI-B) products available. Previously published studies have mostly followed pre-planned dosing schedules and seldom compared use of both products. This study presents a retrospective analysis of the "real-world" dosing requirements of patients on LAI-B., Method: Five clinics provided data for patients commenced on LAI-B between 1 February 2019 and 30 June 2021 for buprenorphine doses and intervals between dosing. The study recorded basic demographic data including age, gender, and previous dose of transmucosal buprenorphine. The Local Institutional Ethics Committee provided approval., Results: Over 3600 individual doses (59 % Buvidal® & 41 % Sublocade®) were administered to 340 individual patients (median age 40 years, 63 % male), with the longest duration in treatment of 856 days. Median estimated duration of a treatment episode was 16.5 months (95%CI: 14.3-19.1). Approximately 94 % transferred from transmucosal buprenorphine (median daily dose 16 mg, range 2-32 mg). Most common LAI-B doses were Sublocade® 100 mg (22.4 %) and Buvidal® Monthly 128 mg (21.5 %); Buvidal® Weekly 24 mg (0.8 %) was least used. 13 % transitioned between LAI-B products. Weekly dose intervals were a median 7 days and monthly doses were given a median of 28 days apart. Overall, 36 % discontinued LAI-B before the census date., Discussions and Conclusions: Most patients who started LAI-B remained in treatment, with similar rates in both products. A small, but appreciable number of people switched brands, suggesting that it remains important to have treatment options available., Competing Interests: Declaration of competing interest MD has received honoraria from Indivior & Camurus. JH has received honoraria from Camurus and Indivior, donated to a humanitarian charity. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors., (Crown Copyright © 2024. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
30. Building bridges to outpatient treatment services for post-overdose care via paramedic buprenorphine field initiation.
- Author
-
Belden C 1st, Kopak A, Coules C, Friesen T, Hall J, and Shukla S
- Subjects
- Humans, Male, Female, Adult, Pilot Projects, Retrospective Studies, Naloxone administration & dosage, Naloxone therapeutic use, Ambulatory Care, Middle Aged, Opiate Substitution Treatment methods, Paramedics, Buprenorphine administration & dosage, Buprenorphine therapeutic use, Opioid-Related Disorders drug therapy, Narcotic Antagonists administration & dosage, Narcotic Antagonists therapeutic use, Emergency Medical Services, Drug Overdose drug therapy
- Abstract
Introduction: Despite sustained efforts to reduce opioid-related overdose fatalities, rates have continued to rise. In many areas, overdose response involves emergency medical service (EMS) personnel administering naloxone and transporting patients to the emergency department (ED). However, a substantial number of patients decline transport, and many EDs do not provide medication for opioid use disorder (MOUD). One approach to filling this gap involves delivering MOUD to overdose patients in the field with trained post-overdose EMS teams who can initiate buprenorphine. In this MOUD field initiation pilot program, a trained EMS Community Paramedicine team initiates buprenorphine in the field and links patients to care. The program includes three pathways to treatment with the first designed for EMS to initiate buprenorphine after overdose reversal when the patient is in withdrawal from naloxone; a second pathway initiates buprenorphine after overdose when the patient is not in withdrawal; and a third enables self-referral via a connection to the community EMS team not necessarily related to a recent overdose., Methods: We conducted a retrospective cohort study of the MOUD field initiation pilot program. Data are from 28 patients who entered care immediately post-overdose initiation of buprenorphine, 21 patients who initiated on buprenorphine while not in naloxone withdrawal, and 37 patients who self-referred to treatment following outreach efforts by paramedicine and peer support professionals., Results: A total of 118 patients initiated buprenorphine during the 12-month study period and 104 (83 %) visited the clinic for their first appointment. Over two thirds (68 %, n = 80) remained engaged in care after 30 days. Retained patients tended to be male, white, uninsured, food insecure, have unstable housing, lack reliable transportation, and report prior involvement with the criminal legal system., Conclusion: The initial 12-month period of the pilot program demonstrated the feasibility of initiating buprenorphine at the site of overdose without requiring transport to the ED and offer self-referral pathways for people experiencing barriers to treatment. Specialized EMS can play a critical role in expanding access to MOUD treatment by bridging the gap between overdose and comprehensive community-based care., Competing Interests: Declaration of competing interest None., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
31. Discontinuation of medication treatment for opioid use disorder after a successful course: The discontinuation phase of the CTN-0100 (RDD) trial.
- Author
-
Shulman M, Provost S, Ohrtman K, Novo P, Meyers-Ohki S, Van Veldhuisen P, Oden N, Otterstatter M, Bailey GL, Liu D, Rotrosen J, Nunes EV, and Weiss RD
- Subjects
- Humans, Adult, Administration, Sublingual, Male, Narcotic Antagonists administration & dosage, Narcotic Antagonists therapeutic use, Female, Opiate Substitution Treatment methods, Research Design, Withholding Treatment, Middle Aged, Buprenorphine administration & dosage, Buprenorphine therapeutic use, Opioid-Related Disorders drug therapy, Naltrexone administration & dosage, Naltrexone therapeutic use, Delayed-Action Preparations
- Abstract
Introduction and Background: Buprenorphine, and extended-release naltrexone, are effective in decreasing opioid use, morbidity and mortality. The available evidence suggests that these medications should be used for long term treatment; however, patients often ask how long they need to be on medication, and whether it would be safe to discontinue. There are sparse data to guide us. The CTN-0100 trial will address this gap in our knowledge by studying participants who have decided to discontinue buprenorphine and extended-release naltrexone for OUD., Research Design and Methods: The trial is a multicenter, randomized, non-blinded study. Participants are stable adult volunteers, on sublingual buprenorphine, extended-release buprenorphine, or extended-release naltrexone, expressing an interest in discontinuing medication. Participants on buprenorphine must be stable for at least 1 year and participants on extended-release naltrexone must be stable for at least 6 months. Participants are engaged in the study for up to 96 weeks, including a flexible taper period, and are then transitioned to follow-up within the trial. All participants are randomly assigned to the study Medical Management (MM) or to MM plus Connections (CHESS health) digital smartphone application aimed at recovery and abstinence (MMD). Sublingual Buprenorphine participants are also randomized (2 × 2 design) to a taper using either sublingual or extended-release buprenorphine., Discussion/conclusion: It is hoped that this trial will provide a rich source of data on management of patients discontinuing medication for opioid use disorder (MOUD) to inform future research and practice. The trial will shed light on which strategies are most likely to lead to long-term success (absence of relapse), and what participant characteristics distinguish those who can safely discontinue MOUD from those who remain at risk of relapse should they discontinue., Clinicaltrials: gov Identifier: NCT04464980., Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:, (Copyright © 2023. Published by Elsevier Inc.)
- Published
- 2024
- Full Text
- View/download PDF
32. Virtual reality-based Mindfulness-Oriented Recovery Enhancement (MORE-VR) as an adjunct to medications for opioid use disorder: a Phase 1 trial.
- Author
-
Garland EL, Recasens M, Taple BJ, Donaldson GW, and Weisberg RB
- Subjects
- Humans, Male, Female, Adult, Middle Aged, Virtual Reality, Treatment Outcome, Heart Rate drug effects, Craving drug effects, Feasibility Studies, Virtual Reality Exposure Therapy methods, Analgesics, Opioid therapeutic use, Analgesics, Opioid administration & dosage, Mindfulness methods, Opioid-Related Disorders therapy, Opioid-Related Disorders drug therapy, Opioid-Related Disorders psychology, Methadone therapeutic use, Methadone administration & dosage, Opiate Substitution Treatment methods, Buprenorphine therapeutic use, Buprenorphine administration & dosage
- Abstract
Introduction: Medications for opioid use disorder (MOUD) are the most effective interventions for this condition, yet many patients discontinue treatment. Though adjunct psychosocial treatments are recommended to increase retention and reduce relapse, the scarcity of trained providers hinders access to and utilization of evidence-based interventions. We conducted a Phase 1 study to assess the feasibility of a virtual reality-delivered Mindfulness-Oriented Recovery Enhancement (MORE-VR) intervention for patients receiving MOUD., Patients and Methods: Patients receiving buprenorphine or methadone for OUD ( N = 34) were scheduled for 8 weekly sessions of MORE-VR. Enrollment and retention rates were analyzed. Participants reported on the usability and acceptability of MORE-VR, opioid use, and craving and affect before and after each VR session. Heart rate was monitored during one session of MORE-VR., Results: Twenty-three participants completed four or more MORE-VR sessions (minimum recommended intervention dose). Participants reported high usability and acceptability of MORE-VR, which had an excellent safety profile. Illicit opioid use decreased significantly from pre- to post-treatment ( F = 4.44, p =.04). We observed a significant within-session decrease in opioid craving ( F = 39.3, p <.001) and negative affect ( F = 36.3, p <.001), and a significant within-session increase in positive affect ( F = 23.6, p <.001). Heart rate shifted during cue-exposure and mindfulness practices ( F = 6.79, p <.001)., Conclusions: High retention, usability and acceptability rates and low adverse events demonstrated that MORE-VR is a feasible, engaging, and safe intervention. Our findings show that MORE-VR can be delivered as an adjunctive intervention to MOUD and suggest that MORE-VR may improve OUD treatment outcomes and modulate autonomic responses. MORE-VR's efficacy will be tested in a subsequent Phase 2 trial., Trial Registration: ClinicalTrials.gov NCT05034276; https://classic.clinicaltrials.gov/ct2/show/NCT05034276.
- Published
- 2024
- Full Text
- View/download PDF
33. The role of recovery peer navigators in retention in outpatient buprenorphine treatment: a retrospective cohort study.
- Author
-
Giraldo A, Shah P, Zerbo E, and Nyaku AN
- Subjects
- Humans, Retrospective Studies, Male, Female, Adult, Middle Aged, Peer Group, Ambulatory Care statistics & numerical data, Healthcare Disparities statistics & numerical data, Ethnicity, Outpatients, Opioid-Related Disorders drug therapy, Buprenorphine therapeutic use, Buprenorphine administration & dosage, Opiate Substitution Treatment methods, Opiate Substitution Treatment statistics & numerical data, Patient Navigation organization & administration, Retention in Care statistics & numerical data
- Abstract
Background: Racial and ethnic disparities are evident in the accessibility of treatment for opioid use disorder (OUD). Even when medications for OUD (MOUD) are accessible, racially and ethnically minoritized groups have higher attrition rates from treatment. Existing literature has primarily identified the specific racial and ethnic groups affected by these disparities, but has not thoroughly examined interventions to address this gap. Recovery peer navigators (RPNs) have been shown to improve access and overall retention on MOUD., Patients and Methods: In this retrospective cohort study, we evaluate the role of RPNs on patient retention in clinical care at an outpatient program in a racially and ethnically diverse urban community. Charts were reviewed of new patients seen from January 1, 2019 through December 31, 2019. Sociodemographic and clinical visit data, including which providers and services were utilized, were collected, and the primary outcome of interest was continuous retention in care. Bivariate analysis was done to test for statistically significant associations between variables by racial/ethnic group and continuous retention in care using Student's t-test or Pearson's chi-square test. Variables with p value ≤0.10 were included in a multivariable regression model., Results: A total of 131 new patients were included in the study. RPNs improved continuous retention in all-group analysis (27.6% pre-RPN compared to 80.2% post-RPN). Improvements in continuous retention were observed in all racial/ethnic subgroups but were statistically significant in the non-Hispanic Black (NHB) group ( p < 0.001). Among NHB, increases in continuous retention were observed post-RPN in patients with male sex ( p < 0.001), public health insurance ( p < 0.001), additional substance use ( p < 0.001), medical comorbidities ( p < 0.001), psychiatric comorbidities ( p = 0.001), and unstable housing ( p = 0.005). Multivariate logistic regression demonstrated that patients who lacked insurance had lower odds of continuous retention compared to patients with public insurance (aOR = 0.17, 95% CI 0.039-0.70, p = 0.015)., Conclusions: RPNs can improve clinical retention for patients with OUD, particularly for individuals experiencing several sociodemographic and clinical factors that are typically correlated with discontinuation of care.
- Published
- 2024
- Full Text
- View/download PDF
34. Rapid induction of transdermal buprenorphine to subcutaneous extended-release buprenorphine for the treatment of opioid use disorder.
- Author
-
Azar P, Schneiderman H, Barron H, Wong JSH, Meyer M, Newman-Azar D, Narimani M, Ignaszewski MJ, Mathew N, Mullen R, Krausz RM, and Maharaj AR
- Subjects
- Humans, Male, Adult, Narcotic Antagonists administration & dosage, Narcotic Antagonists therapeutic use, Female, Opiate Substitution Treatment methods, Injections, Subcutaneous, Middle Aged, Analgesics, Opioid administration & dosage, Analgesics, Opioid adverse effects, Buprenorphine, Naloxone Drug Combination administration & dosage, Buprenorphine, Naloxone Drug Combination therapeutic use, Opioid-Related Disorders drug therapy, Buprenorphine administration & dosage, Buprenorphine therapeutic use, Delayed-Action Preparations, Administration, Cutaneous, Substance Withdrawal Syndrome drug therapy
- Abstract
Background: Buprenorphine is an effective and safe treatment for opioid use disorder, but the requirement for moderate opioid withdrawal symptoms to emerge prior to initiation is a significant treatment barrier., Case Presentation: We report on two cases of hospitalized patients with severe, active opioid use disorder, in which we initiated treatment with transdermal buprenorphine over 48 h, followed by the administration of a single dose of sublingual buprenorphine/naloxone and then extended-release subcutaneous buprenorphine. The patients did not experience precipitated withdrawal and only had mild withdrawal symptoms., Conclusions: This provides preliminary evidence for a rapid induction strategy that may improve tolerability, caregiver burden, and treatment retention as compared to previous induction strategies., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
35. Low-dose overlap initiation with split tablets of buprenorphine in intubated intensive care unit patients with opioid use disorder.
- Author
-
Szczesniak L, Britton S, Rn TB, and Sullivan R
- Subjects
- Humans, Male, Female, Opiate Substitution Treatment methods, Adult, Middle Aged, Narcotic Antagonists therapeutic use, Narcotic Antagonists administration & dosage, Intubation, Intratracheal methods, Buprenorphine administration & dosage, Buprenorphine therapeutic use, Opioid-Related Disorders drug therapy, Intensive Care Units, Analgesics, Opioid administration & dosage
- Abstract
Background: As the opioid public health crisis evolves to include fentanyl and other potent synthetic opioids, more patients are admitted to the hospital with serious complications of drug use and frequently require higher levels of care, including intensive care unit (ICU) admission, for acute and chronic conditions related to opioid use disorder (OUD). This patient population poses a unique challenge when managing sedation and ensuring adequate ventilation while intubated given their high opioid requirements. Starting a patient on medications such as buprenorphine may be difficult for inpatient providers unfamiliar with its use, which may lead to undertreatment of patients with OUD, prolonged mechanical ventilation and length of stay., Methods: We developed a 7-day buprenorphine low dose overlap initiation (LDOI) schedule for patients with OUD admitted to the ICU (Table 1). Buprenorphine tablets were split by pharmacists and placed into pre-made blister packs as a kit to be loaded into the automated medication dispensing machine for nursing to administer daily. An internal quality review validated the appropriate dosing of split-dose tablets. To simplify order entry and increase prescriber comfort with this new protocol, we generated an order set within our electronic health record software with prebuilt buprenorphine titration orders. This protocol was implemented alongside patient and healthcare team education and counseling on the LDOI process, with follow-up offered to all patients upon discharge., Results: Here we report a series of 6 ICU patients started on buprenorphine using the LDOI schedule with split buprenorphine tablets. None of the 6 patients experienced precipitated withdrawal upon buprenorphine initiation using the LDOI schedule, and 5/6 patients were successfully extubated during the buprenorphine initiation. Four of six patients had a decrease in daily morphine milligram equivalents, with 3 patients transitioning to buprenorphine alone., Conclusion: Initiating buprenorphine via LDOI was found to be successful in the development of a protocol for critically ill patients with OUD. We examined LDOI of buprenorphine in intubated ICU patients and found no events of acute precipitated withdrawal. This protocol can be used as a guide for other institutions seeking to start critically ill patients on medication treatment for OUD during ICU admission., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
36. Feasibility of Web-Based Single-Session Empowered Relief in Patients With Chronic Pain Taking Methadone or Buprenorphine: Protocol for a Single-Arm Trial.
- Author
-
Klein MR, Darnall BD, and You DS
- Subjects
- Humans, Prospective Studies, Male, Female, Analgesics, Opioid therapeutic use, Analgesics, Opioid adverse effects, Analgesics, Opioid administration & dosage, Adult, Pain Management methods, Opiate Substitution Treatment methods, Internet-Based Intervention, Internet, Opioid-Related Disorders drug therapy, Middle Aged, Buprenorphine therapeutic use, Buprenorphine administration & dosage, Chronic Pain drug therapy, Chronic Pain psychology, Methadone therapeutic use, Methadone administration & dosage, Feasibility Studies
- Abstract
Background: Chronic pain affects tens of millions of US adults and continues to rise in prevalence. Nonpharmacologic behavioral pain treatments are greatly needed and yet are often inaccessible, particularly in settings where medication prescribing is prioritized., Objective: This study aims to test the feasibility of a live-instructor, web-based 1-session pain relief skills class in an underserved and potentially at-risk population: people with chronic pain prescribed methadone or buprenorphine either solely for pain or for comorbid opioid use disorder (OUD)., Methods: This is a national, prospective, single-arm, uncontrolled feasibility trial. The trial is untethered from medical care; to enhance participants' willingness to join the study, no medical records or drug-monitoring records are accessed. At least 45 participants will be recruited from outpatient pain clinics and from an existing research database of individuals who have chronic pain and are taking methadone or buprenorphine. Patient-reported measures will be collected at 6 time points (baseline, immediately post treatment, 2 weeks, and months 1-3) via a web-based platform, paper, or phone formats to include individuals with limited internet or computer access and low literacy skills. At baseline, participants complete demographic questions and 13 study measures (Treatment Expectations, Body Pain Map, Medication Use, Pain Catastrophizing Scale [PCS], Patient-Reported Outcomes Measurement Information System [PROMIS] Measures, and Opioid Craving Scale). Immediately post treatment, a treatment satisfaction and acceptability measure is administered on a 0 (very dissatisfied) to 10 (completely satisfied) scale, with 3 of these items being the primary outcome (perceived usefulness, participant satisfaction, and likelihood of using the skills). At each remaining time point, the participants complete all study measures minus treatment expectations and satisfaction. Participants who do not have current OUD will be assessed for historical OUD, with presence of OUD (yes or no), and history of OUD (yes or no) reported separately. Feasibility threshold is set as an overall group treatment satisfaction rating of 8 of 10. In-depth qualitative interviews will be conducted with about 10 participants to obtain additional data on patient perceptions, satisfactions, needs, and wants. To assess preliminary efficacy, we will examine changes in pain catastrophizing, pain intensity, pain bothersomeness, sleep disturbance, pain interference, depression, anxiety, physical function, global impression of change, and opioid craving at 1 month post treatment., Results: This project opened to enrollment in September 2021 and completed the recruitment in October 2023. The data collection was completed in February 2024. Results are expected to be published in late 2024., Conclusions: Results from this trial will inform the feasibility and preliminary efficacy of Empowered Relief in this population and will inform the design of a future randomized controlled trial testing web-based Empowered Relief in chronic pain and comorbid OUD., Trial Registration: ClinicalTrials.gov NCT05057988; https://clinicaltrials.gov/study/NCT05057988., International Registered Report Identifier (irrid): DERR1-10.2196/53784., (©Morgan R Klein, Beth D Darnall, Dokyoung S You. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 06.06.2024.)
- Published
- 2024
- Full Text
- View/download PDF
37. Extended-Release Injection vs Sublingual Buprenorphine for Opioid Use Disorder With Fentanyl Use: A Post Hoc Analysis of a Randomized Clinical Trial.
- Author
-
Nunes EV, Comer SD, Lofwall MR, Walsh SL, Peterson S, Tiberg F, Hjelmstrom P, and Budilovsky-Kelley NR
- Subjects
- Humans, Male, Female, Administration, Sublingual, Adult, Double-Blind Method, Middle Aged, Injections, Subcutaneous, Narcotic Antagonists administration & dosage, Narcotic Antagonists therapeutic use, Analgesics, Opioid administration & dosage, Opiate Substitution Treatment methods, Buprenorphine, Naloxone Drug Combination administration & dosage, Buprenorphine, Naloxone Drug Combination therapeutic use, Treatment Outcome, Opioid-Related Disorders drug therapy, Fentanyl administration & dosage, Fentanyl therapeutic use, Buprenorphine administration & dosage, Delayed-Action Preparations
- Abstract
Importance: Fentanyl has exacerbated the opioid use disorder (OUD) and opioid overdose epidemic. Data on the effectiveness of medications for OUD among patients using fentanyl are limited., Objective: To assess the effectiveness of sublingual or extended-release injection formulations of buprenorphine for the treatment of OUD among patients with and without fentanyl use., Design, Setting, and Participants: Post hoc analysis of a 24-week, randomized, double-blind clinical trial conducted at 35 outpatient sites in the US from December 2015 to November 2016 of sublingual buprenorphine-naloxone vs extended-release subcutaneous injection buprenorphine (CAM2038) for patients with OUD subgrouped by presence vs absence of fentanyl or norfentanyl in urine at baseline. Study visits with urine testing occurred weekly for 12 weeks, then 6 times between weeks 13 and 24. Data were analyzed on an intention-to-treat basis from March 2022 to August 2023., Intervention: Weekly and monthly subcutaneous buprenorphine vs daily sublingual buprenorphine-naloxone., Main Outcomes and Measures: Retention in treatment, percentage of urine samples negative for any opioids (missing values imputed as positive), percentage of urine samples negative for fentanyl or norfentanyl (missing values not imputed), and scores on opiate withdrawal scales and visual analog craving scales., Results: Of 428 participants, 123 (subcutaneous buprenorphine, n = 64; sublingual buprenorphine-naloxone, n = 59; mean [SD] age, 39.1 [10.8] years; 75 men [61.0%]) had evidence of baseline fentanyl use and 305 (subcutaneous buprenorphine, n = 149; buprenorphine-naloxone, n = 156; mean [SD] age, 38.1 [11.1] years; 188 men [61.6%]) did not have evidence of baseline fentanyl use. Study completion was similar between the fentanyl-positive (60.2% [74 of 123]) and fentanyl-negative (56.7% [173 of 305]) subgroups. The mean percentage of urine samples negative for any opioid were 28.5% among those receiving subcutaneous buprenorphine and 18.8% among those receiving buprenorphine-naloxone in the fentanyl-positive subgroup (difference, 9.6%; 95% CI, -3.0% to 22.3%) and 36.7% among those receiving subcutaneous buprenorphine and 30.6% among those receiving buprenorphine-naloxone in the fentanyl-negative subgroup (difference, 6.1%; 95% CI, -1.9% to 14.1%), with significant main associations of baseline fentanyl status and treatment group. In the fentanyl-positive subgroup, the mean percentage of urine samples negative for fentanyl during the study was 74.6% among those receiving subcutaneous buprenorphine vs 61.9% among those receiving sublingual buprenorphine-naloxone (difference, 12.7%; 95% CI, 9.6%-15.9%). Opioid withdrawal and craving scores decreased rapidly after treatment initiation across all groups., Conclusions and Relevance: In this post hoc analysis of a randomized clinical trial of sublingual vs extended-release injection buprenorphine for OUD, buprenorphine appeared to be effective among patients with baseline fentanyl use. Patients with fentanyl use had fewer opioid-negative urine samples during the trial compared with the fentanyl-negative subgroup. These findings suggest that the subcutaneous buprenorphine formulation may be more effective at reducing fentanyl use., Trial Registration: ClinicalTrials.gov Identifier: NCT02651584.
- Published
- 2024
- Full Text
- View/download PDF
38. Comparison of the efficacy and safety of transdermal buprenorphine patch to conventional analgesics after operative fixation of extra capsular fracture of proximal femur.
- Author
-
Londhe SB, Patwardhan M, Shah RV, Desouza C, Oak M, and Antao NA
- Subjects
- Humans, Female, Male, Prospective Studies, Treatment Outcome, Aged, Middle Aged, Acetaminophen administration & dosage, Acetaminophen therapeutic use, Administration, Cutaneous, Tramadol administration & dosage, Tramadol therapeutic use, Hip Fractures surgery, Pain Management methods, Pain, Postoperative drug therapy, Buprenorphine administration & dosage, Analgesics, Opioid administration & dosage, Analgesics, Opioid therapeutic use, Transdermal Patch, Pain Measurement
- Abstract
Introduction: Proximal femur fractures are common among older individuals and pose challenges in achieving effective post-operative analgesia. Age-related co-morbidities limit the selection of analgesics in this population. This study aimed to compare the safety and effectiveness of transdermal buprenorphine (TDB) patch with traditional analgesics after fixation of an extracapsular fracture of the proximal femur., Methodology: A prospective randomized controlled study was conducted over a 2-year period, involving 60 patients who underwent surgery for extra capsular intertrochanteric fracture fixation. The patients were randomly assigned to two groups by random envelope method. Group A received an intravenous formulation of paracetamol and tramadol for the initial 48 h, followed by an oral formulation. Group B received a transdermal buprenorphine (TDB) patch delivering 5 mcg/hour immediately after surgery, which continued for 2 weeks postoperatively. During the 14-day monitoring period, patients' pain scores were assessed using the Visual Analog Scale (VAS) at rest and during movement. The primary objective was to maintain a VAS score of 4 or lower. Rescue analgesics were administered if the VAS score reached 6. The secondary objectives included evaluating the quantity of rescue analgesics required and monitoring for any adverse effects or complications., Results: Pain scores at rest and during movement were significantly lower in Group B at all-time points (p-value 0.0006 - ≤ 0.0001), and the requirement for rescue analgesia was also significantly lower in this group. The administration of the TDB patch did not result in any significant adverse effects., Conclusion: TDB patch is secure and offers better compliance and analgesia than other analgesics in the postoperative period whilst treating proximal femur extra capsular fracture., Competing Interests: Declaration of competing interest The authors declare there are no financial conflicts of interest to disclose., (Copyright © 2024 Elsevier Ltd. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
39. Direct induction onto high-dose long-acting injectable buprenorphine: A case series.
- Author
-
Naren T, Cook J, and MacCartney P
- Subjects
- Adult, Humans, Male, Middle Aged, Delayed-Action Preparations, Injections, Narcotic Antagonists administration & dosage, Retrospective Studies, Buprenorphine administration & dosage, Opiate Substitution Treatment methods, Opioid-Related Disorders drug therapy
- Abstract
Introduction: This case series reports on five patients with opioid use disorder (OUD) who were commenced directly onto high-dose long-acting injectable buprenorphine (LAIB)., Method: A retrospective audit and manual review of the electronic medical record at cohealth Innerspace was conducted for patients who had been directly inducted onto high-dose LAIB., Results: Five cases were identified on retrospective manual file review. All patients identified were males aged between 33 and 60 years old and were treated with either high-dose Buvidal Weekly and Monthly preparations. No immediate significant adverse effects were noticed and 4 out of 5 remain engaged with treatment., Conclusion: This case series shows it is possible to directly induct patients with OUD onto high-dose LAIB preparations without significant side effects or harm to the patient and could be considered a viable option in the treatment of patients with OUD., Competing Interests: DisclosureThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Dr Thileepan Naren has received speaking honoraria from Camurus.
- Published
- 2024
- Full Text
- View/download PDF
40. High-Dose Buprenorphine Initiation in the Management of Opioid Use Disorder in Pregnancy.
- Author
-
Berry M, Kiefer MK, Hinely KA, Bowden H, Jordan A, Vilensky M, and Rood KM
- Subjects
- Adult, Female, Humans, Pregnancy, Young Adult, Analgesics, Opioid administration & dosage, Analgesics, Opioid therapeutic use, Narcotic Antagonists administration & dosage, Narcotic Antagonists therapeutic use, Retrospective Studies, Buprenorphine administration & dosage, Buprenorphine therapeutic use, Opiate Substitution Treatment methods, Opioid-Related Disorders drug therapy, Pregnancy Complications drug therapy
- Abstract
Buprenorphine is commonly used as a treatment for opioid use disorder (OUD). Transition to buprenorphine traditionally has been done using a low-dose initiation regimen due to concerns surrounding precipitated withdrawal. There are increasing data supporting use of a high-dose initiation regimen in the nonpregnant population. This retrospective case series describes six individuals with OUD who underwent high-dose buprenorphine initiation in pregnancy. There were no instances of sedation, respiratory depression, supplemental oxygen use, or death. All individuals were successfully transitioned to buprenorphine. These findings provide support for high-dose buprenorphine initiation in pregnancy, but future large studies are needed., Competing Interests: Financial Disclosure The authors did not report any potential conflicts of interest., (Copyright © 2024 by the American College of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
41. Extended-release versus oral buprenorphine as opioid maintenance treatment during pregnancy-maternal and neonatal outcomes.
- Author
-
Kanervo M, Tupola S, Nikkola E, Rantakari K, and Kahila H
- Subjects
- Humans, Female, Pregnancy, Adult, Infant, Newborn, Administration, Oral, Neonatal Abstinence Syndrome drug therapy, Pregnancy Outcome, Administration, Sublingual, Narcotic Antagonists administration & dosage, Narcotic Antagonists therapeutic use, Analgesics, Opioid administration & dosage, Cohort Studies, Young Adult, Buprenorphine, Naloxone Drug Combination administration & dosage, Buprenorphine, Naloxone Drug Combination therapeutic use, Opioid-Related Disorders drug therapy, Opiate Substitution Treatment methods, Buprenorphine administration & dosage, Buprenorphine therapeutic use, Delayed-Action Preparations, Pregnancy Complications drug therapy
- Abstract
Objective: To get information on subcutaneous extended-release buprenorphine as opioid maintenance treatment during pregnancy, we compared it to orally administered buprenorphine and buprenorphine-naloxone treatments. We hypothesized that maternal and neonatal outcomes do not differ between the treatment groups. Study design In this population-based cohort study, 60 pregnant individuals receiving non-changed opioid maintenance treatment for opioid use disorder with a buprenorphine product from the time before conception to the time after delivery and their newborns were included. They were divided into three groups based on the pharmacotherapy with subcutaneous extended-release buprenorphine, sublingual buprenorphine, or buprenorphine-naloxone. Statistical analyses were conducted using Fischer's exact tests, ANOVA tests, and Kruskal-Wallis tests. All the statistical tests were two-tailed., Results: The frequency of pregnancy or delivery complications did not significantly differ between the group receiving extended-release buprenorphine and the other groups. During pregnancy, 38 % of the women used illicit drugs concomitantly, with equal frequency in the extended-release buprenorphine group and the other groups. Of the neonates, 93 % were born full-term and 90 % got at least eight Apgar points in one minute age, without significant differences between the groups (p = 0.57). The need for pharmacotherapy for neonatal opioid withdrawal syndrome was the lowest in the extended-release buprenorphine group (25 %) and highest in the sublingual buprenorphine group (67 %). Still, the difference between the treatment groups did not reach statistical significance (p = 0.17). Among all neonates, the breastfed infants were less likely to receive pharmacotherapy for withdrawal symptoms than the formula-fed ones (p = 0.048)., Conclusions: Extended-release buprenorphine with steady drug concentration seems to be a promising pharmacotherapy option during pregnancy for mothers. Maternal health during pregnancy may contribute to the well-being of newborns. Larger trials are urgently needed to confirm these results.., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
42. Pregnancy Rates Among Women Treated with Medication for Opioid Use Disorder.
- Author
-
Bello JK, Xu KY, Salas J, Bedrick BS, and Grucza RA
- Subjects
- Humans, Female, Pregnancy, Adult, Retrospective Studies, Young Adult, Cross-Over Studies, United States epidemiology, Analgesics, Opioid therapeutic use, Analgesics, Opioid administration & dosage, Pregnancy Complications drug therapy, Narcotic Antagonists therapeutic use, Narcotic Antagonists administration & dosage, Adolescent, Opioid-Related Disorders drug therapy, Opioid-Related Disorders epidemiology, Opiate Substitution Treatment methods, Naltrexone therapeutic use, Naltrexone administration & dosage, Buprenorphine therapeutic use, Buprenorphine administration & dosage, Pregnancy Rate, Methadone therapeutic use, Methadone administration & dosage
- Abstract
Background: Treatment-seeking people with opioid use disorder (OUD) who are capable of pregnancy need accurate information about the potential impact of medication to treat OUD (MOUD) on fertility to make informed choices about treatment that are consistent with their reproductive wishes. There is a dearth of research on fertility associated with MOUD receipt in birthing people with OUD., Objective: To estimate the association between treatment with MOUD and odds of conception among birthing people using national administrative claims., Design: Retrospective case-crossover study using multi-state US administrative data (2006-2016). Dates of conception were estimated from delivery dates and served as "case" days for which MOUD exposures were compared to those on all other ("control") days of insurance enrollment., Participants: Treatment-seeking people with OUD with a delivery during the observation period., Main Measures: Odds ratios for conception from within-person fixed effects models were modeled as a function of exposure to MOUD (buprenorphine, methadone, extended-release depot naltrexone, or oral naltrexone) using conditional logistic regression., Key Results: A total of 21,928 births among 19,133 people with OUD were identified. In the sample, 5873 people received buprenorphine, 1825 methadone, 486 extended-release naltrexone, and 714 oral naltrexone. Participants could receive more than one type of MOUD. Mean age was 28.2 years (SD = 2.2; range = 16-45), with 76.2% having Medicaid. vs. commercial insurance. Compared to no MOUD, periods of methadone (aOR = 0.55 [95% CI = 0.48-0.63]) or buprenorphine receipt (aOR = 0.84 [0.77-0.91]) were associated with fewer conceptions. Treatment periods with extended-release depot naltrexone compared to no medication were associated with higher odds of conception (aOR = 1.75 [1.22-2.50]) and there was no significant difference in conception with oral naltrexone (aOR = 1.02 [0.67-1.54])., Conclusions: The association between MOUD and odds of conception among birthing people varied by type of MOUD, with extended-release naltrexone associated with higher odds of conceiving compared to no treatment. Clinical studies are urgently needed to investigate these findings further., (© 2024. The Author(s), under exclusive licence to Society of General Internal Medicine.)
- Published
- 2024
- Full Text
- View/download PDF
43. Neuraxial clonidine is not associated with lower post-cesarean opioid consumption or pain scores in parturients on chronic buprenorphine therapy: a retrospective cohort study.
- Author
-
Taylor MG, Bauchat JR, Sorabella LL, Wanderer JP, Feng X, Shotwell MS, and Ende HB
- Subjects
- Humans, Female, Retrospective Studies, Adult, Pregnancy, Pain Measurement methods, Pain Measurement drug effects, Opioid-Related Disorders, Cohort Studies, Opiate Substitution Treatment methods, Clonidine administration & dosage, Buprenorphine administration & dosage, Buprenorphine therapeutic use, Cesarean Section methods, Pain, Postoperative drug therapy, Analgesics, Opioid administration & dosage, Analgesics, Opioid therapeutic use
- Abstract
Purpose: Adequate post-cesarean delivery analgesia can be difficult to achieve for women diagnosed with opioid use disorder receiving buprenorphine. We sought to determine if neuraxial clonidine administration is associated with decreased opioid consumption and pain scores following cesarean delivery in women receiving chronic buprenorphine therapy., Methods: This was a retrospective cohort study at a tertiary care teaching hospital of women undergoing cesarean delivery with or without neuraxial clonidine administration while receiving chronic buprenorphine. The primary outcome was opioid consumption (in morphine milligram equivalents) 0-6 h following cesarean delivery. Secondary outcomes included opioid consumption 0-24 h post-cesarean, median postoperative pain scores 0-24 h, and rates of intraoperative anesthetic supplementation. Multivariable analysis evaluating the adjusted effects of neuraxial clonidine on outcomes was conducted using linear regression, proportional odds model, and logistic regression separately., Results: 196 women met inclusion criteria, of which 145 (74%) received neuraxial clonidine while 51 (26%) did not. In univariate analysis, there was no significant difference in opioid consumption 0-6 h post-cesarean delivery between the clonidine (8 [IQR 0, 15]) and control (1 [IQR 0, 8]) groups (P = 0.14). After adjusting for potential confounders, there remained no significant association with neuraxial clonidine administration 0-6 h (Difference in means 2.77, 95% CI [- 0.89 to 6.44], P = 0.14) or 0-24 h (Difference in means 8.56, 95% CI [- 16.99 to 34.11], P = 0.51)., Conclusion: In parturients receiving chronic buprenorphine therapy at the time of cesarean delivery, neuraxial clonidine administration was not associated with decreased postoperative opioid consumption, median pain scores, or the need for intraoperative supplementation., (© 2024. The Author(s) under exclusive licence to Japanese Society of Anesthesiologists.)
- Published
- 2024
- Full Text
- View/download PDF
44. Relationship between opioid cross-tolerance during buprenorphine stabilization and return to opioid use during buprenorphine dose tapering.
- Author
-
Greenwald MK, Sogbesan T, and Moses TEH
- Subjects
- Humans, Male, Adult, Female, Double-Blind Method, Drug Tapering methods, Opiate Substitution Treatment methods, Substance Withdrawal Syndrome drug therapy, Dose-Response Relationship, Drug, Opioid-Related Disorders drug therapy, Young Adult, Heroin Dependence drug therapy, Middle Aged, Narcotic Antagonists administration & dosage, Buprenorphine administration & dosage, Hydromorphone administration & dosage, Analgesics, Opioid administration & dosage, Drug Tolerance
- Abstract
Rationale: Opioid injection drug use (IDU) has been linked to a more severe pattern of use (e.g. tolerance, overdose risk) and shorter retention in treatment, which may undermine abstinence attempts., Objectives: This secondary data analysis of four human laboratory studies investigated whether current opioid IDU modulates subjective abuse liability responses to high-dose hydromorphone during intermediate-dose buprenorphine stabilization (designed to suppress withdrawal but allow surmountable agonist effects), and whether hydromorphone response magnitude predicts latency of return to opioid use during buprenorphine dose-tapering., Methods: Regular heroin users not currently seeking treatment (n = 54; 29 current injectors, 25 non-injectors) were stabilized on 8-mg/day sublingual buprenorphine and assessed for subjective responses (e.g. 'liking', craving) to hydromorphone 24-mg intramuscular challenge (administered 16-hr post-buprenorphine) under randomized, double-blinded, controlled conditions. A subgroup (n = 35) subsequently completed a standardized 3-week outpatient buprenorphine dose-taper, paired with opioid-abstinent contingent reinforcement, and were assessed for return to opioid use based on thrice-weekly urinalysis and self-report., Results: During buprenorphine stabilization, IDU reported lower 'liking' of buprenorphine and post-hydromorphone peak 'liking', 'good effect' and 'high' compared to non-IDU. Less hydromorphone peak increase-from-baseline in 'liking' (which correlated with less hydromorphone-induced craving suppression) predicted significantly faster return to opioid use during buprenorphine dose-tapering., Conclusions: In these buprenorphine-stabilized regular heroin users, IDU is associated with attenuated 'liking' response (more cross-tolerance) to buprenorphine and to high-dose hydromorphone challenge and, in turn, this cross-tolerance (but not IDU) predicts faster return to opioid use. Further research should examine mechanisms that link cross-tolerance to treatment response., (© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
45. Direct rotation from a fentanyl patch to a buprenorphine patch in a patient with chronic pain.
- Author
-
Steenhof N, Flannery J, and Lee J
- Subjects
- Humans, Administration, Cutaneous, Male, Middle Aged, Treatment Outcome, Opiate Substitution Treatment, Female, Buprenorphine administration & dosage, Buprenorphine adverse effects, Fentanyl administration & dosage, Fentanyl adverse effects, Chronic Pain drug therapy, Analgesics, Opioid administration & dosage, Analgesics, Opioid adverse effects, Transdermal Patch
- Abstract
Transitioning a patient with chronic pain from a fentanyl patch to a buprenorphine patch has not been well described in the literature. Even after a patient removes their fentanyl patch, the residual fentanyl in the skin continues to be absorbed for hours. Due to the risk of precipitated withdrawal when initiating buprenorphine, this transition is a more challenging opioid rotation to plan safely. We report a case of a patient who had been using a fentanyl patch for over 10 years and was successfully rotated directly to a buprenorphine patch.
- Published
- 2024
- Full Text
- View/download PDF
46. Post-operative pain control in patients on buprenorphine or methadone for opioid use disorder.
- Author
-
Quaye A, Tsafnat T, Richard JM, Stoddard H, and Gagnon DJ
- Subjects
- Humans, Male, Female, Retrospective Studies, Middle Aged, Adult, Pain Management methods, Pain Measurement, Aged, Elective Surgical Procedures, Buprenorphine therapeutic use, Buprenorphine administration & dosage, Pain, Postoperative drug therapy, Pain, Postoperative diagnosis, Methadone therapeutic use, Methadone administration & dosage, Opioid-Related Disorders prevention & control, Analgesics, Opioid therapeutic use, Opiate Substitution Treatment
- Abstract
Objective: This study aimed to determine whether there is a difference in pain scores and opioid consumption after elective surgery in patients maintained on methadone or buprenorphine for opioid use disorder (OUD). Additionally, we investigated the impact of continuing or discontinuing methadone or buprenorphine on post-operative pain outcomes., Design: A single-center retrospective cohort study., Setting: Tertiary care medical center., Patients and Participants: Adults aged 18 years or older with OUD maintained on buprenorphine or methadone who underwent elective surgery between January 1, 2017, and January 1, 2021., Interventions: Patients were identified through electronic medical records, and demographic and clinical data were collected., Main Outcome Measures: The primary outcome was opioid consumption at 24 hours post-operatively, measured in milligram morphine equivalents. The secondary outcome was opioid consumption and pain scores up to 72 hours post-operatively, assessed using a numeric rating scale., Results: This study included 366 patients (64 percent on buprenorphine and 36 percent on methadone). Opioid utilization significantly increased when buprenorphine was not administered post-operatively. Both groups exhibited comparable total opioid consumption during the post-operative period. In the buprenorphine cohort, pain scores differed significantly based on the receipt of medications for OUD post-operatively., Conclusions: This study reinforces existing evidence supporting the continuation of medications for opioid use disorder, specifically buprenorphine and methadone, during the perioperative period. Dissemination of guideline recommendations is essential to ensure optimal post-operative pain management for this patient population.
- Published
- 2024
- Full Text
- View/download PDF
47. Compared implementation of the long-acting buprenorphine treatment buvidal in four European countries.
- Author
-
Rolland B, Matheson C, Kaski A, Kosim M, Roncero C, and Vorspan F
- Subjects
- Humans, Europe, Surveys and Questionnaires, Buprenorphine administration & dosage, Buprenorphine therapeutic use, Buprenorphine economics, Opioid-Related Disorders drug therapy, Delayed-Action Preparations, Opiate Substitution Treatment methods, Opiate Substitution Treatment economics, Analgesics, Opioid administration & dosage, Analgesics, Opioid therapeutic use
- Abstract
Background: Buvidal is the only depot buprenorphine currently available in Europe. Buvidal offers a new treatment paradigm, which may require some adjustment in the national regulatory frameworks for opioid agonist treatments (OATs), as well as the national care systems., Research Design and Methods: Data on the national dissemination of Buvidal, types of populations treated, and the national regulatory framework and care organization system through which Buvidal has been implemented were compared between the UK, Finland, Spain, and France, using a qualitative survey., Results: In 2022, the proportion of people on OAT who received Buvidal was 2.1% in the UK, 60-65% in Finland, 1% in Spain, and 0.3% in France. In both Finland and the UK, the cost of the medication is covered by the national health system, whereas, in Spain and France, Buvidal is accessible only in specialized centers, which must carry its cost. Other national features may explain the gaps in Buvidal use, including the baseline level of OAT coverage, which was high in both France and Spain., Conclusions: Important national discrepancies are found regarding Buvidal dissemination among people on OAT.
- Published
- 2024
- Full Text
- View/download PDF
48. The dynamics of more-than-human care in depot buprenorphine treatment: A new materialist analysis of Australian patients' experiences.
- Author
-
Barnett A, Pienaar K, Lubman DI, Arunogiri S, Phan V, Hayes V, Lintzeris N, and Savic M
- Subjects
- Humans, Male, Female, Adult, Middle Aged, Australia, Qualitative Research, Narcotic Antagonists administration & dosage, Interviews as Topic, Methadone administration & dosage, Buprenorphine administration & dosage, Opioid-Related Disorders drug therapy, Opiate Substitution Treatment, Delayed-Action Preparations
- Abstract
Background: Long-acting injectable depot buprenorphine has become an important treatment option for the management of opioid dependence. However, little is known about patients' experiences of depot buprenorphine and its embodied effects. This qualitative study aims to explore patients' experiences of depot buprenorphine treatment, including how it feels within the body, experiences of dosing cycles across time, and how this form of treatment relies on wider ecologies of care beyond the clinical encounter., Methods: Participants were recruited from sites in Sydney, regional New South Wales, and Melbourne, Victoria, Australia. Thirty participants (16 men, 14 women) participated in semi-structured interviews. Participants had histories of both heroin and prescription opioid consumption, and opioid agonist therapy including daily dosing of buprenorphine and methadone., Results: Our analysis illuminates: (1) how patients' expectations and concerns about treatment are linked to past embodied experiences of withdrawal and uncertainty about the effectiveness of depot buprenorphine; (2) the diverse meanings patients attribute to the depot buprenorphine substrate 'under the skin'; and, (3) how depot buprenorphine is embedded within wider ecologies of care, such as counselling and social supports., Conclusion: Our analysis destabilises commonplace assumptions about a linear, causal relationship between the pharmacological action of depot buprenorphine and experiences of treatment. Instead, it highlights patients' variable experiences of depot buprenorphine, tracing the everyday practices, embodied feelings, expectations and wider networks of care that shape patient experiences. We conclude with some reflections on the implications of our analysis for alcohol and other drug treatment, specifically how they might inform the design of client education materials and care., Competing Interests: Declaration of competing interest ROLE OF FUNDING SOURCE This research was supported by funding from Camurus AB. SA is supported by a National Health and Medical Research Council Investigator Grant (GNT2008193). SA has received honoraria for advisory board attendance from Camurus and Indivior, and speaker honoraria from Camurus, Indivior, Gilead, Janssen and Servier unrelated to this work. VH has received funding from Camurus AB and ViiV Healthcare to provide training. NL has received honoraria for attendance on Advisory Boards for Indivior, Mundipharma and Chiesi Pharmaceuticals, and has received research funding from Camurus AB for unrelated research. DL has previously received speaking honoraria from AstraZeneca, Camurus, Indivior, Janssen, Servier, Shire and Lundbeck and has provided consultancy advice to Lundbeck and Indivior. DL is supported by a NHMRC Investigator grant (1196892). Other than support received from Camurus AB for this project, AB, MS, KP and VP have no funding disclosures to declare., (Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
49. Predictive factors for acceptance of a long-acting opiate substitution treatment studied through social representations and internalized stigma.
- Author
-
Lacroix A, Puybaret V, Villéger P, Zattoni-Leroy J, Cantaloube S, Chevalier C, and Nubukpo P
- Subjects
- Humans, Male, Female, Adult, Middle Aged, France, Substance Withdrawal Syndrome psychology, Opiate Substitution Treatment psychology, Opioid-Related Disorders psychology, Opioid-Related Disorders drug therapy, Social Stigma, Buprenorphine administration & dosage, Buprenorphine therapeutic use, Patient Acceptance of Health Care psychology
- Abstract
Objectives: Opioid use disorder is a public health problem worldwide with a treatment gap partially due to sociocultural representation and stigma. Taking the opportunity of an authorization to a subcutaneous (SC) injectable solution of buprenorphine, the first and only injectable treatment for opioid dependence available in France, we investigate potential obstacles to its implementation in France., Methods: This study aimed to define the factors predicting the acceptance of a new SC form of opiate substitution treatment (OST) by comparing the social representations using an adapted version of the Explanatory Model Interview Catalogue (EMIC) and the internalized stigma of intravenous drug injection using the Internalized Stigma of Mental Illness Inventory (ISMI) between participants receiving OST likely to accept the SC form or not. We also observed whether the fear of an opiate withdrawal syndrome could influence this choice., Results: Fifty OST patients were included, 54% of them accepted a new SC form of OST. Perceived causes of drug injection measured with EMIC were significantly lower among participants who would not accept the new SC form. No significant difference was found regarding the total score of the adapted ISMI or its items. The fear of opiate withdrawal syndrome did not seem to be statistically related to acceptance of a long-acting SC OST in either group. The most discriminating combination of factors in predicting patient acceptance of such treatment was related to the perceived causes of drug injection associated with a severe Diagnostic and Statistical Manual of Mental Disorders 5th version (DSM-5) diagnosis, and a lower alcohol consumption., Conclusions: We observed significant differences in social representations but not in internalized stigma between the two groups. Moreover, the predictive factors linked to the acceptance of a new SC form of OST suggest a multifactorial combination of elements that will have to be tested in a larger and prospective study delivering long-acting high-dose buprenorphine., (Copyright © 2023 Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
50. Characterizing acute and postsurgical pain management in patients receiving buprenorphine or buprenorphine/naloxone.
- Author
-
Jones AC, Tillman F 3rd, Kahlon C, Seys R, and Pepin M
- Subjects
- Humans, Male, Female, Retrospective Studies, Middle Aged, Adult, Aged, Drug Overdose, Narcotic Antagonists administration & dosage, Narcotic Antagonists therapeutic use, Pain, Postoperative drug therapy, Opioid-Related Disorders drug therapy, Analgesics, Opioid administration & dosage, Analgesics, Opioid adverse effects, Analgesics, Opioid therapeutic use, Buprenorphine administration & dosage, Buprenorphine therapeutic use, Buprenorphine adverse effects, Acute Pain drug therapy, Buprenorphine, Naloxone Drug Combination therapeutic use, Buprenorphine, Naloxone Drug Combination administration & dosage, Pain Management methods
- Abstract
Background: There is currently a clinical dilemma in treating acute pain in patients receiving long-term buprenorphine products., Methods: This is a retrospective cohort review involving patients receiving long-term buprenorphine therapy who either underwent a surgical procedure or presented to an emergency department (ED) for acute pain between January 1, 2012 and January 1, 2022. Patients were excluded if opioids were prescribed 30 days before the index date. Chart reviews were conducted to characterize buprenorphine treatment strategies and the addition of new pain medications. Chart review revealed (1) incidence of opioid use disorder (OUD) relapse, (2) hospital re-presentation for pain or OUD, (3) fatal and non-fatal overdose, and (4) all-cause mortality and suicidality. Descriptive statistics were used to analyze results., Results: A total of 70 of 259 screened patients met inclusion criteria. The mean (±SD) age was 50.3 ± 13 years, 92.9% male, 64.3% White, and 78.6% had an OUD diagnosis. While 84.3% presented to the ED, 15.7% underwent surgical procedures. For the primary endpoint, the total daily dose of buprenorphine or buprenorphine/naloxone from index date to discharge was continued in 90.0%, increased in 2.9%, decreased in 1.4%, and discontinued in 5.7% of cases. At discharge, 46.2% were prescribed an additional pain medication. A total of 7.1% re-presented for pain or OUD relapse, 15.7% experienced an OUD relapse, 1.4% experienced new-onset suicidality, and 1.4% experience all-cause mortality within 90 days of the index date. No fatal or non-fatal opioid overdoses were observed., Conclusion: The most commonly observed practice was continuing buprenorphine doses in patients with acute or postsurgical pain, which was effective and safe. Although further data is necessary to fully elucidate these findings, the data herein may suggest that clinicians can safely continue buprenorphine doses in the acute pain setting in patients receiving these products chronically., Competing Interests: Disclosure The authors declare no relevant conflicts of interest or financial relationships., (Published by Elsevier Inc.)
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.